SkyePharma_NN
annual_JJ
report_NN
2002_CD
1_CD
Accounting_GER
policies_NN
until_IN
earned_VBN
,_,
when_RB
they_TPP3
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
income_NN
._.
Manufacturing_GER
and_PHC
distribution_NOMZ
revenues_NN
principally_RB
comprise_VPRT
contract_NN
Accounting_GER
convention_NOMZ
and_PHC
presentation_NOMZ
manufacturing_GER
fees_NN
invoiced_VBD
to_PIN
third_JJ
parties_NN
and_PHC
income_NN
from_PIN
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
product_NN
sales_NN
._.
cost_NN
convention_NOMZ
and_CC
in_PIN
accordance_NN
with_PIN
applicable_JJ
UK_NN
accounting_GER
standards_NN
._.
The_DT
principal_JJ
accounting_GER
policies_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN
Research_NN
and_PHC
development_NOMZ
costs_NN
applied_VBD
consistently_RB
,_,
except_PIN
for_PIN
the_DT
implementation_NOMZ
of_PIN
FRS19_NN
:_:
Research_NN
costs_NN
are_VPRT [PASS]
charged_VBN
as_IN
an_DT
expense_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
Deferred_NN
Tax_NN
,_,
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
The_DT
results_NN
for_PIN
the_DT
year_NN
all_QUAN
relate_VPRT
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
Development_NOMZ
costs_NN
are_VPRT [SPAU] [PASS]
also_RB
recognized_VBN [PRIV]
as_IN
an_DT
to_TO
continuing_VBG
operations_NOMZ
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN
expense_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
incurred_VBN
,_,
unless_COND
all_QUAN
of_PIN
the_DT
prepared_JJ
on_PIN
a_DT
going_VBG
concern_NN
basis_NN
._.
criteria_NN
are_VPRT [PASS]
met_VBN
for_PIN
asset_NN
recognition_NOMZ
._.
The_DT
major_JJ
asset_NN
recognition_NOMZ
criteria_NN
include_VPRT
:_:
the_DT
ability_NOMZ
to_TO
define_VB
clearly_RB
the_DT
product_NN
or_CC
process_NN
,_,
New_NN
accounting_GER
policies_NN
and_PHC
requirements_NOMZ
demonstration_NOMZ
of_PIN
its_PIT
technical_JJ
feasibility_NOMZ
and_CC
that_THVC
a_DT
commercial_JJ
The_DT
Group_NN
has_VPRT [PEAS]
implemented_VBN
FRS_NN
19_CD
:_:
Deferred_JJ
Tax_NN
._.
The_DT
FRS_NN
market_NN
for_PIN
it_PIT
exists_VPRT
._.
Development_NOMZ
costs_VPRT
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
do_EMPH
requires_VPRT [SUAV]
deferred_VBN
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
not_XX0
exceed_VB
the_DT
probable_JJ
net_JJ
amount_NN
to_TO
be_VB [PASS]
recovered_VBN
in_PIN
marketing_VBG
basis_NN
,_,
rather_CONJ
than_PIN
the_DT
partial_JJ
provision_NN
basis_NN
adopted_VBN [WZPAST]
in_PIN
2001_CD
the_DT
product_NN
or_CC
process_NN
and_CC
they_TPP3
are_VPRT [PASS]
amortised_VBN
over_IN
the_DT
estimated_VBN [PRIV]
and_CC
earlier_TIME
years_NN
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
19_CD
has_VPRT [PEAS]
had_VBN
no_SYNE
material_JJ
economic_JJ
life_NN
._.
impact_NN
on_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Once_TIME
the_DT
Group_NN
has_VPRT [PEAS]
achieved_VBN
sustained_VBN
profitability_NOMZ
,_,
the_DT
Directors_NN
will_PRMD
consider_VB [PRIV]
the_DT
Foreign_JJ
currency_NN
transactions_NOMZ
appropriateness_NOMZ
of_PIN
recognizing_VBG [PRIV]
a_DT
deferred_JJ
tax_NN
asset_NN
in_PIN
respect_NN
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
are_VPRT [PASS]
recorded_VBN
of_PIN
losses_NN
carried_VBD
forward_RB
._.
in_PIN
local_JJ
currency_NN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
on_PIN
the_DT
date_NN
of_PIN
transaction_NOMZ
._.
Assets_NN
and_PHC
liabilities_NOMZ
expressed_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
Consolidation_NOMZ
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
at_PIN
the_DT
exchange_NN
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
The_DT
consolidated_JJ
financial_JJ
information_NOMZ
includes_VPRT
the_DT
financial_JJ
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
which_WDT [WHSUB]
relate_VPRT
to_PIN
the_DT
statements_NOMZ
for_PIN
the_DT
Company_NN
,_,
its_PIT
subsidiary_NN
undertakings_GER
and_PHC
retranslation_NOMZ
of_PIN
net_JJ
assets_NN
of_PIN
overseas_PLACE
companies_NN
are_VPRT [PASS]
taken_VBN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
and_PHC
results_NN
of_PIN
associated_VBN
directly_RB
to_PIN
reserves_NN
._.
All_QUAN
other_JJ
foreign_JJ
exchange_NN
differences_NN
are_VPRT
undertakings_GER
._.
Intra-group_JJ
sales_NN
and_PHC
profits_NN
are_VPRT [PASS]
eliminated_VBN
fully_AMP
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
they_TPP3
on_PIN
consolidation_NOMZ
._.
The_DT
results_NN
of_PIN
subsidiaries_NN
sold_VBN
or_CC
acquired_VBN
are_VPRT
arise_VB
._.
The_DT
Group_NN
uses_VPRT
the_DT
average_JJ
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
included_VBN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_VPRT
up_RP
to_PIN
the_DT
date_NN
during_PIN
the_DT
year_NN
to_TO
translate_VB
the_DT
results_NN
of_PIN
overseas_PLACE
subsidiaries_NN
of_PIN
their_TPP3
sale_NN
or_CC
from_PIN
their_TPP3
date_NN
of_PIN
acquisition_NOMZ
respectively_RB
._.
The_DT
into_PIN
sterling_GER
and_PHC
year-end_NN
rates_NN
to_TO
translate_VB
the_DT
net_JJ
assets_NN
of_PIN
share_NN
of_PIN
results_NN
of_PIN
associated_VBN
undertakings_GER
sold_VBD
or_CC
acquired_VBD
are_VPRT [BEMA]
those_DEMO
undertakings_GER
._.
included_VBN [PASTP]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_VPRT
up_RP
to_PIN
the_DT
date_NN
of_PIN
their_TPP3
sale_NN
or_CC
from_PIN
the_DT
date_NN
of_PIN
their_TPP3
acquisition_NOMZ
respectively_RB
._.
Pension_NN
costs_NN
The_DT
costs_NN
of_PIN
the_DT
Groups_NN
defined_VBN
contribution_NOMZ
pension_NN
Where_RB
the_DT
Group_NN
has_VPRT
contractual_JJ
agreements_NOMZ
with_PIN
other_JJ
arrangements_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
participants_NN
to_TO
engage_VB
in_PIN
joint_JJ
activities_NOMZ
that_TSUB
do_VPRT
not_XX0
create_VB
year_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
The_DT
costs_NN
of_PIN
the_DT
Groups_NN
defined_VBN
benefits_NN
an_DT
entity_NOMZ
carrying_VBG [WZPRES]
on_PIN
a_DT
trade_NN
or_CC
business_NOMZ
of_PIN
its_PIT
own_JJ
,_,
they_TPP3
are_VPRT
scheme_NN
are_VPRT [PASS]
charged_VBN
on_PIN
a_DT
systematic_JJ
basis_NN
allowing_VBG [SUAV] [WZPRES]
for_PIN
the_DT
accounted_VBN
for_PIN
as_IN
a_DT
joint_JJ
arrangement_NOMZ
._.
The_DT
Group_NN
includes_VPRT
its_PIT
expected_VBN [PRIV]
pension_NN
cost_NN
over_IN
the_DT
service_NN
lives_NN
of_PIN
employees_NN
,_,
based_VBN
share_NN
of_PIN
the_DT
assets_NN
,_,
liabilities_NOMZ
and_PHC
cash_NN
flows_NN
in_PIN
such_JJ
joint_JJ
on_PIN
actuarial_JJ
advice_NN
._.
arrangements_NOMZ
measured_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
each_QUAN
arrangement_NOMZ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
usually_RB
pro-rata_PRED
to_PIN
the_DT
Groups_NN
interest_NN
Employee_NN
Share_NN
Plans_NN
in_PIN
the_DT
joint_JJ
arrangement_NOMZ
._.
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
employees_NN
under_IN
share_NN
option_NOMZ
and_PHC
share_NN
award_NN
schemes_NN
._.
In_PIN
respect_NN
of_PIN
award_NN
Revenue_NN
recognition_NOMZ
schemes_NN
the_DT
Group_NN
provides_VPRT
finance_NN
to_PIN
an_DT
employee_NN
share_NN
Turnover_NN
comprises_VPRT
contract_NN
development_NOMZ
and_PHC
licensing_GER
,_,
ownership_NN
trust_NN
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
royalty_NN
and_PHC
manufacturing_GER
and_PHC
distribution_NOMZ
income_NN
._.
Contract_NN
to_TO
meet_VB
the_DT
Groups_NN
obligation_NOMZ
to_TO
provide_VB
shares_NN
when_RB
employees_NN
development_NOMZ
and_PHC
licensing_GER
income_NN
represents_VPRT
amounts_NN
invoiced_VBD
exercise_NN
their_TPP3
award_NN
._.
The_DT
difference_NN
between_PIN
the_DT
purchase_NN
price_NN
to_PIN
customers_NN
for_PIN
services_NN
rendered_VBN
under_IN
development_NOMZ
and_CC
of_PIN
the_DT
shares_NN
and_CC
the_DT
exercise_NN
price_NN
of_PIN
the_DT
award_NN
is_VPRT [PASS]
charged_VBN
,_,
or_CC
licensing_GER
agreements_NOMZ
including_VBG [WZPRES]
milestone_NN
payments_NOMZ
and_CC
credited_VBN
,_,
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
periods_NN
of_PIN
service_NN
technology_NN
access_NN
fees_NN
._.
Contract_NN
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
award_NN
was_VBD [PASS]
granted_VBN [SUAV]
._.
earned_VBN
and_CC
non-refundable_JJ
and_ANDC
when_RB
there_EX
are_VPRT
no_SYNE
future_JJ
obligations_NOMZ
pursuant_JJ
to_PIN
the_DT
revenue_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
The_DT
costs_NN
of_PIN
running_VBG
the_DT
employee_NN
share_NN
ownership_NN
trust_NN
are_VPRT
contract_NN
terms_NN
._.
Refundable_JJ
contract_NN
revenue_NN
is_VPRT [PASS]
treated_VBN
as_IN
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
accrue_VPRT
._.
deferred_VBN
until_IN
such_JJ
time_NN
as_IN
it_PIT
is_VPRT
no_RB
longer_RB
refundable_JJ
._.
Royalty_NN
income_NN
represents_VPRT
income_NN
earned_VBD
as_IN
a_DT
percentage_NN
of_PIN
product_NN
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
employee_NN
share_NN
ownership_NN
trust_NN
are_VPRT [PASS]
accounted_VBN
sales_NN
._.
Advance_NN
royalties_NN
received_VBD
are_VPRT [PASS]
treated_VBN
as_IN
deferred_JJ
income_NN
for_PIN
as_IN
fixed_JJ
asset_NN
investments_NOMZ
at_PIN
cost_NN
less_JJ
accrual_NN
for_PIN
costs_NN
charged_VBN
._.
notes_NN
to_PIN
the_DT
57_CD
financial_JJ
statements_NOMZ
1_CD
Accounting_GER
policies_NN
continued_VBD
Current_JJ
asset_NN
investments_NOMZ
Investments_NOMZ
held_VBD [PRIV]
other_JJ
than_PIN
for_PIN
continuing_VBG
use_NN
in_PIN
the_DT
business_NOMZ
are_VPRT [BEMA]
Intangible_PRED
fixed_VBN
assets_NN
classified_VBN
as_IN
current_JJ
asset_NN
investments_NOMZ
and_CC
recorded_VBN
in_PIN
the_DT
balance_NN
Intangible_JJ
fixed_JJ
assets_NN
comprise_VPRT
goodwill_NN
,_,
intellectual_JJ
property_NN
sheet_NN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Goodwill_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
purchase_NN
consideration_NOMZ
and_CC
the_DT
Liquid_NN
resources_NN
Groups_NN
share_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
,_,
is_VPRT
Liquid_NN
resources_NN
comprise_VPRT
short-term_JJ
bank_NN
and_CC
commercial_JJ
capitalized_JJ
and_PHC
amortised_JJ
over_IN
a_DT
period_NN
of_PIN
20_CD
years_NN
or_CC
less_JJ
in_PIN
line_NN
deposits_NN
with_PIN
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
one_CD
year_NN
._.
with_PIN
the_DT
Directors_NN
view_NN
of_PIN
its_PIT
useful_JJ
economic_JJ
life_NN
._.
Prior_RB
to_PIN
the_DT
introduction_NOMZ
of_PIN
FRS_NN
10_CD
,_,
the_DT
policy_NN
adopted_VBN [WZPAST]
was_VBD
to_TO
write_VB [PUBV]
off_PIN
goodwill_NN
Leased_VBN
and_PHC
hired_VBN
assets_NN
to_PIN
reserves_NN
._.
As_IN
permitted_VBN
by_PIN
FRS_NN
10_CD
goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
to_PIN
reserves_NN
Leasing_GER
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
substantially_RB
all_QUAN
in_PIN
previous_JJ
years_NN
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
reinstated_VBN
on_PIN
the_DT
balance_NN
sheet_NN
and_CC
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
treated_VBN
as_IN
adjustments_NOMZ
to_PIN
such_JJ
goodwill_NN
have_VPRT [PEAS]
been_VBN [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
._.
finance_NN
leases_NN
,_,
as_IN
if_COND
the_DT
asset_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
outright_RB
._.
The_DT
Goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
tangible_JJ
fixed_JJ
assets_NN
and_CC
the_DT
capital_NN
element_NOMZ
and_PHC
loss_NN
account_NN
in_PIN
the_DT
event_NN
of_PIN
disposal_NN
of_PIN
the_DT
related_JJ
business_NOMZ
._.
of_PIN
amounts_NN
owed_VBN [WZPAST]
to_PIN
the_DT
finance_NN
company_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
is_VPRT [PASS]
included_VBN
in_PIN
creditors_NN
as_IN
amounts_NN
falling_VBG [WZPRES]
due_JJ
either_CC
within_PIN
or_CC
after_IN
Intellectual_NN
property_NN
comprises_VPRT
acquired_VBN
patents_NN
,_,
trade_NN
marks_NN
,_,
more_EMPH
than_PIN
one_CD
year_NN
._.
Repayments_NOMZ
are_VPRT [PASS]
treated_VBN
as_IN
consisting_VBG
of_PIN
both_DT
know-how_NN
and_CC
other_JJ
similarly_CONJ
identified_VBN
rights_NN
._.
These_DEMP
are_VPRT [BEMA]
recorded_JJ
capital_NN
and_PHC
interest_NN
with_PIN
the_DT
interest_NN
element_NOMZ
being_VBG [WZPRES] [PASS]
charged_VBN
to_PIN
the_DT
at_PIN
their_TPP3
fair_JJ
value_NN
at_PIN
acquisition_NOMZ
date_NN
and_CC
are_VPRT [PASS]
amortised_VBN
in_PIN
equal_JJ
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
proportion_NOMZ
to_PIN
the_DT
outstanding_JJ
obligations_NOMZ
._.
instalments_NOMZ
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
economic_JJ
lives_NN
,_,
from_PIN
the_DT
Payments_NOMZ
under_IN
operating_VBG
leases_NN
and_CC
short-term_JJ
hire_NN
contracts_NN
date_NN
when_RB
the_DT
transfer_NN
of_PIN
technology_NN
is_VPRT [BEMA]
complete_PRED
._.
The_DT
period_NN
over_IN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
fall_VPRT
due_JJ
._.
which_WDT [SERE]
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
derive_VB
economic_JJ
benefits_NN
does_VPRT
not_XX0
exceed_VB
20_CD
years_NN
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
internally_RB
developed_VBN
Convertible_JJ
debt_NN
intellectual_JJ
property_NN
are_VPRT [SPAU] [PASS]
generally_RB
treated_VBN
as_IN
research_NN
and_CC
On_PIN
issue_NN
,_,
convertible_JJ
debt_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
net_JJ
proceeds_NN
development_NOMZ
costs_NN
._.
Development_NOMZ
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
under_IN
after_IN
deducting_VBG
issue_NN
costs_NN
._.
On_PIN
conversion_NN
the_DT
amount_NN
recognized_VBD [PRIV] [THATD]
the_DT
criteria_NN
stated_VBN [PUBV]
above_PLACE
._.
in_PIN
shareholders_NN
funds_NN
in_PIN
respect_NN
of_PIN
the_DT
shares_NN
issued_VBN [WZPAST]
is_VPRT [BEMA]
equal_PRED
to_PIN
the_DT
carrying_VBG
value_NN
at_PIN
the_DT
date_NN
of_PIN
conversion_NN
._.
Interest_NN
payable_JJ
on_PIN
Tangible_JJ
fixed_JJ
assets_NN
convertible_JJ
debt_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
unwind_VB
the_DT
issue_NN
costs_NN
and_CC
any_QUAN
Tangible_JJ
fixed_JJ
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
less_JJ
discount_NN
on_PIN
issue_NN
at_PIN
a_DT
constant_JJ
rate_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
tangible_JJ
fixed_JJ
assets_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
,_,
less_JJ
estimated_VBN [PRIV]
Deferred_JJ
consideration_NOMZ
residual_JJ
value_NN
,_,
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
life_NN
._.
The_DT
rates_NN
Provisions_NN
for_PIN
deferred_JJ
consideration_NOMZ
comprise_VPRT
the_DT
fair_JJ
value_NN
of_PIN
and_CC
bases_NN
are_VPRT
as_IN
follows_VPRT
:_:
contingent_JJ
consideration_NOMZ
arising_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
._.
The_DT
eventual_JJ
outcome_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Groups_NN
future_JJ
performance_NN
and_CC
certain_JJ
Freehold_NN
land_NN
not_XX0
depreciated_VBD
contractual_JJ
terms_NN
._.
Provisions_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
by_PIN
the_DT
Freehold_NN
buildings_GER
2_CD
%_NN
5_CD
%_NN
straight_JJ
line_NN
Directors_NN
,_,
and_ANDC
changes_NN
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
the_DT
contingent_JJ
Short_JJ
leasehold_NN
property_NN
period_NN
of_PIN
lease_NN
consideration_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
an_DT
adjustment_NOMZ
to_PIN
goodwill_NN
or_CC
the_DT
Plant_NN
,_,
equipment_NOMZ
and_PHC
fixtures_NN
10_CD
%_NN
33_CD
%_NN
straight_JJ
line_NN
underlying_VBG [WZPRES]
asset_NN
value_NN
._.
Where_RB
the_DT
effect_NN
of_PIN
the_DT
time_NN
value_NN
of_PIN
money_NN
Motor_NN
vehicles_NN
20_CD
%_NN
straight_JJ
line_NN
is_VPRT
material_NN
,_,
provisions_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
at_PIN
their_TPP3
present_JJ
value_NN
,_,
and_ANDC
the_DT
Finance_NN
leases_VPRT
period_NN
of_PIN
lease_NN
interest_NN
element_NOMZ
arising_VBG [WZPRES]
on_PIN
discounting_VBG
the_DT
liability_NOMZ
is_VPRT [PASS]
recorded_VBN
as_IN
interest_NN
payable_JJ
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
it_PIT
unwinds_VPRT
._.
Fixed_JJ
asset_NN
investments_NOMZ
Investments_NOMZ
that_TSUB
are_VPRT [PASS]
held_VBN [PRIV]
for_PIN
continuing_VBG
use_NN
in_PIN
the_DT
business_NOMZ
are_VPRT [PASS]
Deferred_VBN
taxation_NOMZ
classified_VBN
as_IN
fixed_JJ
asset_NN
investments_NOMZ
and_CC
recorded_VBN
in_PIN
the_DT
balance_NN
Deferred_VBN
taxation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
timing_NN
differences_NN
which_WDT [WHOBJ]
at_PIN
the_DT
sheet_NN
at_PIN
cost_NN
or_CC
Directors_NN
valuation_NOMZ
,_,
less_JJ
provision_NN
for_PIN
permanent_JJ
balance_NN
sheet_NN
date_NN
result_NN
in_PIN
an_DT
obligation_NOMZ
to_TO
pay_VB
more_EMPH
tax_NN
or_CC
a_DT
right_JJ
diminution_NOMZ
in_PIN
value_NN
._.
to_TO
pay_VB
less_JJ
tax_NN
at_PIN
a_DT
future_JJ
date_NN
,_,
at_PIN
rates_NN
expected_VBN [PRIV]
to_TO
apply_VB
when_RB
they_TPP3
crystallise_VPRT
based_VBN
on_PIN
current_JJ
tax_NN
rates_NN
and_PHC
law_NN
._.
Deferred_JJ
tax_NN
assets_NN
Impairment_NOMZ
of_PIN
fixed_JJ
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
The_DT
carrying_VBG
values_NN
of_PIN
fixed_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
not_XX0
that_DEMO
they_TPP3
will_PRMD
be_VB [PASS]
recovered_VBN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
assets_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
year_NN
impairment_NOMZ
reviews_NN
are_VPRT [PASS]
conducted_VBN
for_PIN
acquired_VBN
goodwill_NN
and_CC
intangible_JJ
assets_NN
._.
Impairment_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
Financial_NN
instruments_NOMZ
higher_JJ
of_PIN
net_JJ
realisable_JJ
value_NN
and_PHC
value_NN
in_PIN
use_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
measured_VBN
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
hedge_VB
its_PIT
by_PIN
reference_NN
to_PIN
discounted_JJ
future_JJ
cash_NN
flows_NN
._.
Any_QUAN
provision_NN
for_PIN
exposure_NN
to_PIN
fluctuations_NOMZ
in_PIN
interest_NN
and_CC
foreign_JJ
exchange_NN
rates_NN
._.
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
year_NN
Specifically_RB
,_,
the_DT
Group_NN
uses_VPRT
interest_NN
rate_NN
swaps_NN
,_,
forward_RB
currency_NN
concerned_VBN
._.
Receipts_NN
and_PHC
payments_NOMZ
on_PIN
interest_NN
rate_NN
swaps_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
an_DT
accruals_NN
basis_NN
,_,
over_IN
the_DT
life_NN
of_PIN
the_DT
Stock_NN
and_PHC
work-in-progress_NN
swap_NN
,_,
as_IN
an_DT
adjustment_NOMZ
to_PIN
interest_NN
payable_JJ
._.
Gains_NN
and_PHC
losses_NN
on_PIN
Stock_NN
and_PHC
work-in-progress_NN
are_VPRT [PASS]
valued_VBN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
forward_JJ
currency_NN
contracts_NN
and_PHC
currency_NN
options_NOMZ
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
net_JJ
realisable_JJ
value_NN
and_CC
calculated_VBN [PRIV]
using_VBG
the_DT
first-in_PIN [STPR]
,_,
first-out_PIN
basis_NN
._.
until_IN
the_DT
period_NN
that_TOBJ
the_DT
foreign_JJ
currency_NN
exposure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
._.
Option_NOMZ
premia_NN
are_VPRT [PASS]
deferred_VBN
in_PIN
the_DT
balance_NN
sheet_NN
and_CC
recognized_VBN [PRIV]
upon_PIN
the_DT
maturity_NOMZ
of_PIN
the_DT
option_NOMZ
agreement_NOMZ
._.
notes_NN
to_PIN
the_DT
financial_JJ
58_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
2_CD
Segmental_JJ
analysis_NN
The_DT
Groups_NN
operations_NOMZ
relate_VPRT
wholly_RB
to_PIN
one_CD
class_NN
of_PIN
business_NOMZ
,_,
pharmaceuticals_NN
._.
Further_JJ
analysis_NN
of_PIN
turnover_NN
,_,
operating_VBG
profit_NN
loss_NN
and_CC
net_JJ
assets_NN
by_PIN
geographical_JJ
area_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
,_,
together_RB
with_PIN
an_DT
analysis_NN
of_PIN
cost_NN
of_PIN
sales_NN
._.
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
a_DT
Turnover_NN
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
Contract_NN
development_NOMZ
and_PHC
licensing_GER
Milestone_NN
payments_NOMZ
47,736_CD
28,379_CD
Research_NN
and_PHC
development_NOMZ
costs_NN
recharged_VBD
7,705_CD
9,857_CD
55,441_CD
38,236_CD
Royalties_NN
receivable_JJ
6,751_CD
1,468_CD
Manufacturing_GER
and_PHC
distribution_NOMZ
7,381_CD
6,422_CD
69,573_CD
46,126_CD
By_PIN
location_NOMZ
of_PIN
customer_NN
:_:
North_NN
America_NN
34,047_CD
5,482_CD
UK_NN
21,000_CD
21,411_CD
Europe_NN
10,333_CD
16,511_CD
Rest_VPRT
of_PIN
the_DT
world_NN
4,193_CD
2,722_CD
69,573_CD
46,126_CD
By_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
Europe_NN
34,449_CD
30,268_CD
North_NN
America_NN
35,124_CD
15,858_CD
69,573_CD
46,126_CD
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
b_NN
Cost_NN
of_PIN
sales_NN
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
Contract_NN
development_NOMZ
and_PHC
licensing_GER
12,649_CD
7,917_CD
Royalties_NN
payable_JJ
1,374_CD
572_CD
Manufacturing_GER
and_PHC
distribution_NOMZ
10,807_CD
10,331_CD
24,830_CD
18,820_CD
59_CD
2_CD
Segmental_JJ
analysis_NN
continued_VBD
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
c_NN
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
1,333_CD
9,377_CD
By_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
UK_NN
7,695_CD
6,840_CD
Europe_NN
7,652_CD
6,985_CD
North_NN
America_NN
4,759_CD
5,244_CD
Operating_GER
profit_NN
loss_NN
4,716_CD
5,099_CD
Associated_NN
undertaking_GER
578_CD
Net_JJ
interest_NN
payable_JJ
3,383_CD
3,700_CD
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
1,333_CD
9,377_CD
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
d_SYM
Net_JJ
assets_NN
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
124,270_CD
95,145_CD
By_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
UK_NN
151,673_CD
136,410_CD
Europe_NN
69,489_CD
74,268_CD
North_NN
America_NN
42,086_CD
33,003_CD
124,270_CD
95,145_CD
3_CD
Other_JJ
operating_GER
income_NN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
have_VPRT [PEAS]
provided_VBN
a_DT
total_NN
of_PIN
$_$
30_CD
million_CD
between_PIN
2000_CD
and_CC
2002_CD
,_,
to_TO
fund_VB
the_DT
clinical_JJ
development_NOMZ
and_CC
regulatory_JJ
submission_NN
of_PIN
DepoMorphine_NN
,_,
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
portion_NOMZ
of_PIN
future_JJ
royalty_NN
and_PHC
revenue_NN
streams_NN
from_PIN
DepoMorphine_NN
,_,
Xatral_NN
OD_NN
,_,
Solaraze_NN
and_PHC
DepoCyt_NN
._.
Income_NN
of_PIN
9.7_CD
million_CD
2001_CD
:_:
6.3_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
as_IN
other_JJ
operating_GER
income_NN
under_IN
this_DEMO
agreement_NOMZ
on_PIN
a_DT
cost_NN
to_TO
complete_VB
basis_NN
._.
No_SYNE
royalty_NN
payments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
under_IN
this_DEMO
agreement_NOMZ
during_PIN
the_DT
year_NN
._.
In_PIN
March_NN
2002_CD
the_DT
Group_NN
announced_VBD [PUBV]
another_DT
transaction_NOMZ
under_IN
which_WDT
Paul_NN
Capital_NN
will_PRMD
pay_VB
SkyePharma_NN
a_DT
further_JJ
$_$
30_CD
million_CD
during_PIN
2002_CD
and_CC
2003_CD
,_,
principally_RB
to_TO
fund_VB
the_DT
clinical_JJ
development_NOMZ
of_PIN
Propofol_NN
IDD-D_NN
and_PHC
HFA-formoterol_NN
._.
In_PIN
return_NN
,_,
SkyePharma_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
sell_VB
a_DT
portion_NOMZ
of_PIN
the_DT
potential_JJ
future_NN
royalty_NN
and_PHC
revenue_NN
streams_NN
from_PIN
these_DEMP
,_,
and_ANDC
seven_CD
other_JJ
products_NN
from_PIN
the_DT
drug_NN
pipeline_NN
to_PIN
Paul_NN
Capital_NN
._.
Income_NN
of_PIN
4.5_CD
million_CD
2001_CD
:_:
nil_NN
was_VBD [PASS]
recognized_VBN [PRIV]
as_IN
other_JJ
operating_GER
income_NN
under_IN
this_DEMO
agreement_NOMZ
on_PIN
a_DT
cost_NN
to_TO
complete_VB
basis_NN
._.
Royalty_NN
payments_NOMZ
of_PIN
0.7_CD
million_CD
$_$
1_CD
million_CD
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
under_IN
this_DEMO
agreement_NOMZ
during_PIN
the_DT
year_NN
,_,
and_ANDC
are_VPRT [PASS]
included_VBN
within_PIN
royalties_NN
payable_JJ
._.
notes_NN
to_PIN
the_DT
financial_JJ
60_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
4_CD
Operating_GER
profit_NN
loss_NN
Operating_GER
profit_NN
loss_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Auditors_NN
remuneration_JJ
audit_NN
of_PIN
SkyePharma_NN
PLC_NN
194_CD
93_CD
audit_NN
of_PIN
subsidiary_NN
undertakings_GER
overseas_PLACE
160_CD
101_CD
Fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
auditors_NN
UK_NN
firm_NN
1,045_CD
499_CD
auditors_NN
overseas_PLACE
firms_NN
214_CD
240_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
owned_VBN
assets_NN
5,616_CD
4,343_CD
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
485_CD
435_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
fixed_JJ
assets_NN
amortisation_NOMZ
of_PIN
goodwill_NN
3,799_CD
2,844_CD
amortisation_NOMZ
of_PIN
intellectual_JJ
property_NN
2,483_CD
1,282_CD
Research_NN
and_PHC
development_NOMZ
expenses_NN
current_JJ
year_NN
expenditure_NN
29,285_CD
17,918_CD
amortisation_NOMZ
of_PIN
deferred_VBN
expenditure_NN
224_CD
201_CD
Operating_GER
lease_NN
rentals_NN
hire_VB
of_PIN
plant_NN
and_PHC
machinery_NN
434_CD
266_CD
other_JJ
3,336_CD
3,659_CD
It_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
policy_NN
to_TO
employ_VB
the_DT
auditors_NN
on_PIN
assignments_NOMZ
additional_JJ
to_PIN
their_TPP3
statutory_JJ
audit_NN
duties_NN
where_RB
their_TPP3
expertise_NN
and_PHC
experience_NN
with_PIN
the_DT
Group_NN
are_VPRT [BEMA]
important_PRED
,_,
principally_RB
tax_NN
advice_NN
and_CC
due_JJ
diligence_NN
reporting_VBG [PUBV] [WZPRES]
on_PIN
acquisitions_NOMZ
,_,
or_CC
where_RB
they_TPP3
are_VPRT [PASS]
awarded_VBN
assignments_NOMZ
on_PIN
a_DT
competitive_JJ
basis_NN
._.
During_PIN
the_DT
year_NN
the_DT
auditors_NN
earned_VBD
the_DT
following_VBG
non-audit_JJ
fees_NN
from_PIN
the_DT
Group_NN
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Due_JJ
diligence_NN
and_CC
other_JJ
audit-related_JJ
work_NN
311_CD
215_CD
Tax_NN
advice_NN
681_CD
297_CD
Accounting_GER
advice_NN
and_CC
regulatory_JJ
returns_NN
267_CD
227_CD
Total_JJ
non-audit_JJ
fees_NN
1,259_CD
739_CD
5_CD
Employees_NN
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Employment_NOMZ
costs_NN
:_:
Wages_NN
and_PHC
salaries_NN
20,614_CD
15,502_CD
Social_NN
security_NOMZ
costs_NN
3,091_CD
2,451_CD
Pension_NN
costs_NN
1,525_CD
822_CD
25,230_CD
18,775_CD
The_DT
average_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
year_NN
was_VBD
as_IN
follows_VPRT
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
Number_NN
Number_NN
Pharmaceuticals_NN
492_CD
411_CD
61_CD
6_CD
Interest_NN
receivable_NN
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Interest_NN
1,081_CD
1,215_CD
Share_NN
of_PIN
interest_NN
receivable_NN
of_PIN
associate_JJ
36_CD
1,081_CD
1,251_CD
7_CD
Interest_NN
payable_JJ
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Interest_NN
payable_JJ
on_PIN
bank_NN
loans_NN
,_,
overdrafts_NN
and_CC
other_JJ
loans_NN
:_:
Repayable_JJ
within_PIN
five_CD
years_NN
,_,
not_XX0
by_PIN
instalments_NOMZ
88_CD
91_CD
Repayable_JJ
within_PIN
five_CD
years_NN
,_,
by_PIN
instalments_NOMZ
112_CD
470_CD
Repayable_JJ
wholly_RB
or_CC
partly_DWNT
in_PIN
more_EMPH
than_PIN
five_CD
years_NN
373_CD
360_CD
Finance_NN
leases_VPRT
130_CD
170_CD
Interest_NN
on_PIN
convertible_JJ
bonds_NN
3,761_CD
3,860_CD
4,464_CD
4,951_CD
8_CD
Taxation_NOMZ
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
,_,
is_VPRT [PASS]
analyzed_VBN
over_IN
its_PIT
component_NN
parts_NN
as_IN
follows_VPRT
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
UK_NN
146_CD
1,269_CD
Overseas_PLACE
1,187_CD
10,646_CD
1,333_CD
9,377_CD
Current_JJ
taxation_NOMZ
charge_NN
based_VBN [WZPAST]
on_PIN
profits_NN
for_PIN
the_DT
year_NN
:_:
Overseas_NN
taxation_NOMZ
224_CD
75_CD
224_CD
75_CD
Overseas_PLACE
taxation_NOMZ
relates_VPRT
principally_RB
to_TO
withholding_VBG
tax_NN
paid_VBN [WZPAST]
on_PIN
remittance_NN
of_PIN
milestones_NN
to_PIN
the_DT
US_FPP1
and_PHC
royalties_NN
to_PIN
Switzerland_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
recoverable_PRED
._.
There_EX
was_VBD
no_SYNE
deferred_JJ
tax_NN
component_NN
in_PIN
the_DT
tax_NN
charge_NN
for_PIN
the_DT
years_NN
presented_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
estimated_VBN [PRIV]
total_JJ
tax_NN
losses_NN
available_JJ
to_TO
be_VB [PASS]
set_VBN
off_PIN
against_PIN
future_JJ
taxable_JJ
profits_NN
of_PIN
178.9_CD
million_CD
31_CD
December_NN
2001_CD
:_:
163.9_CD
million_CD
._.
These_DEMO
losses_NN
arise_VPRT
primarily_RB
in_PIN
the_DT
UK_NN
,_,
Switzerland_NN
and_PHC
US_FPP1
._.
Of_PIN
the_DT
178.9_CD
million_CD
of_PIN
losses_NN
carried_VBD
forward_RB
,_,
0.3_CD
million_CD
expire_VPRT
in_PIN
2003_CD
,_,
52.0_CD
million_CD
expire_VPRT
between_PIN
2004_CD
and_CC
2006_CD
,_,
120.8_CD
million_CD
expire_VPRT
from_PIN
2007_CD
onwards_NN
and_CC
5.8_CD
million_CD
of_PIN
losses_NN
may_POMD
be_VB [PASS]
carried_VBN
forward_RB
indefinitely_RB
._.
The_DT
above_PLACE
charges_NN
reconcile_VPRT
with_PIN
the_DT
applicable_JJ
UK_NN
statutory_JJ
corporation_NOMZ
tax_NN
rate_NN
as_IN
follows_VPRT
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
%_NN
%_NN
Statutory_NN
UK_NN
Corporation_NOMZ
tax_NN
rate_NN
30.0_CD
30.0_CD
Tax_NN
rate_NN
differences_NN
18.2_CD
19.0_CD
Permanent_JJ
differences_NN
19.1_CD
16.9_CD
Tax_NN
losses_NN
not_XX0
recognized_VBN [PRIV]
as_IN
deferred_JJ
tax_NN
assets_NN
23.6_CD
35.0_CD
Other_JJ
items_NN
not_XX0
recognized_VBN [PRIV]
as_IN
deferred_JJ
tax_NN
assets_NN
26.9_CD
31.7_CD
Effective_JJ
tax_NN
rate_NN
16.8_CD
0.8_CD
notes_NN
to_PIN
the_DT
financial_JJ
62_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
9_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
Basic_JJ
and_PHC
diluted_JJ
attributable_JJ
profit_NN
loss_NN
000_CD
1,109_CD
9,452_CD
Basic_JJ
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
000_CD
577,018_CD
526,250_CD
Dilutive_JJ
potential_JJ
Ordinary_NN
Shares_NN
000_CD
20,077_CD
Diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
000_CD
597,095_CD
526,250_CD
For_PIN
diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
,_,
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
assume_VB [PRIV]
conversion_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
Ordinary_NN
Shares_NN
._.
In_PIN
2001_CD
there_EX
was_VBD
no_SYNE
difference_NN
between_PIN
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
Ordinary_NN
Share_NN
since_OSUB
all_QUAN
potential_JJ
Ordinary_NN
Shares_NN
were_VBD [BEMA]
anti-dilutive_PRED
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
Trust_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
._.
10_CD
Intangible_JJ
fixed_JJ
assets_NN
Intellectual_NN
Development_NOMZ
Goodwill_NN
property_NN
costs_NN
Total_JJ
Group_NN
000 000 000 000_CD
Cost_NN
At_PIN
1_CD
January_NN
2002_CD
75,762_CD
30,496_CD
1,716_CD
107,974_CD
Exchange_NN
adjustments_NOMZ
663_CD
62_CD
725_CD
Additions_NOMZ
285_CD
3,401_CD
3,686_CD
Acquisitions_NOMZ
3,970_CD
3,970_CD
At_PIN
31_CD
December_NN
2002_CD
80,017_CD
34,560_CD
1,778_CD
116,355_CD
Amortisation_NOMZ
At_PIN
1_CD
January_NN
2002_CD
6,154_CD
2,974_CD
618_CD
9,746_CD
Exchange_NN
adjustments_NOMZ
82_CD
6_CD
88_CD
Charge_NN
for_PIN
the_DT
year_NN
3,799_CD
2,483_CD
224_CD
6,506_CD
At_PIN
31_CD
December_NN
2002_CD
9,953_CD
5,539_CD
848_CD
16,340_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2001_CD
69,608_CD
27,522_CD
1,098_CD
98,228_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002_CD
70,064_CD
29,021_CD
930_CD
100,015_CD
In_PIN
May_POMD
2002_CD
,_,
SkyePharma_NN
acquired_VBD
the_DT
entire_JJ
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
for_PIN
3.6_CD
million_CD
in_PIN
cash_NN
and_CC
the_DT
assumption_NOMZ
of_PIN
0.4_CD
million_CD
of_PIN
net_JJ
liabilities_NOMZ
._.
The_DT
acquired_VBN
rights_NN
included_VBD
Bioglans_NN
Biosphere_NN
injectable_JJ
technology_NN
and_CC
those_DEMO
rights_NN
to_PIN
DermaStick_NN
,_,
Crystalip_NN
and_PHC
ES-Gel_NN
topical_JJ
technologies_NN
that_TSUB
had_VBD [PEAS]
remained_VBN
with_PIN
Bioglan_NN
after_IN
the_DT
January_NN
2001_CD
development_NOMZ
and_PHC
commercialisation_NOMZ
licensing_GER
agreement_NOMZ
with_PIN
Bioglan_NN
._.
Tangible_JJ
fixed_JJ
assets_NN
include_VPRT
net_JJ
book_NN
value_NN
of_PIN
2,384,000_CD
31_CD
December_NN
2001_CD
:_:
2,314,000_CD
in_PIN
respect_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
._.
Land_NN
and_PHC
Office_NN
and_CC
other_JJ
Motor_NN
buildings_GER
equipment_NOMZ
vehicles_NN
Total_JJ
Company_NN
000 000 000 000_CD
Cost_NN
At_PIN
1_CD
January_NN
2002 107 477_CD
75_CD
659_CD
Additions_NOMZ
46_CD
46_CD
Disposals_NN
191_CD
191_CD
At_PIN
31_CD
December_NN
2002 107 332_CD
75_CD
514_CD
Depreciation_NOMZ
At_PIN
1_CD
January_NN
2002_CD
65_CD
377_CD
74_CD
516_CD
Charge_NN
for_PIN
the_DT
year_NN
11_CD
41_CD
1_CD
53_CD
Disposals_NN
189_CD
189_CD
At_PIN
31_CD
December_NN
2002_CD
76_CD
229_CD
75_CD
380_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2001_CD
42_CD
100_CD
1_CD
143_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002 31 103 134_CD
notes_NN
to_PIN
the_DT
financial_JJ
64_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
12_CD
Fixed_NN
Asset_NN
Investments_NOMZ
a_DT
Group_NN
Unlisted_NN
Own_NN
investments_NOMZ
shares_NN
Total_JJ
000 000 000_CD
At_PIN
1_CD
January_NN
2002_CD
13,659_CD
552_CD
14,211_CD
Additions_NOMZ
5,215_CD
1,070_CD
6,285_CD
Charge_NN
for_PIN
the_DT
year_NN
594_CD
594_CD
At_PIN
31_CD
December_NN
2002_CD
18,874_CD
1,028_CD
19,902_CD
Astralis_NN
Limited_NN
Astralis_NN
Ltd_NN
is_VPRT [BEMA]
an_DT
emerging_VBG
biotechnology_NN
company_NN
based_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
engaged_VBD
primarily_RB
in_PIN
the_DT
research_NN
and_PHC
development_NOMZ
of_PIN
novel_NN
treatments_NOMZ
for_PIN
immune_JJ
system_NN
disorders_NN
and_PHC
skin_NN
diseases_NN
._.
The_DT
company_NN
is_VPRT [SPAU]
currently_RB
developing_VBG
two_CD
products_NN
._.
Its_PIT
primary_JJ
product_NN
,_,
Psoraxine_NN
,_,
is_VPRT [BEMA]
an_DT
innovative_JJ
vaccine_NN
under_IN
development_NOMZ
for_PIN
the_DT
treatment_NOMZ
of_PIN
psoriasis_NN
._.
The_DT
companys_NN
second_JJ
product_NN
is_VPRT [BEMA]
for_PIN
the_DT
treatment_NOMZ
of_PIN
leishmaniasis_NN
._.
During_PIN
the_DT
year_NN
SkyePharma_NN
acquired_VBD
a_DT
further_JJ
750,000_CD
series_NN
A_DT
convertible_JJ
preferred_JJ
shares_NN
of_PIN
Astralis_NN
Limited_NN
for_PIN
5.2_CD
million_CD
$_$
7.5_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
the_DT
total_JJ
SkyePharma_NN
holding_GER
was_VBD [BEMA]
200,000_CD
common_JJ
shares_NN
,_,
20,000_CD
warrants_NN
and_CC
1,750,000_CD
series_NN
A_DT
convertible_JJ
preferred_JJ
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
23.0_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
._.
The_DT
shares_NN
,_,
warrants_NN
and_CC
convertible_JJ
preferred_JJ
shares_NN
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
cost_NN
of_PIN
12.7_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
Astralis_NN
had_VBD
net_JJ
assets_NN
of_PIN
4.9_CD
million_CD
and_CC
a_DT
retained_VBN
loss_NN
for_PIN
the_DT
year_NN
of_PIN
12.2_CD
million_CD
._.
Transition_NOMZ
Therapeutics_NN
Inc._NN
is_VPRT [BEMA]
a_DT
biopharmaceutical_JJ
company_NN
based_VBN [WZPAST]
in_PIN
Canada_NN
and_CC
engaged_VBN
primarily_RB
in_PIN
the_DT
business_NOMZ
of_PIN
developing_VBG
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
multiple_JJ
sclerosis_NN
,_,
diabetes_NN
and_PHC
restenosis_NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
total_JJ
SkyePharma_NN
holding_GER
of_PIN
Transition_NOMZ
was_VBD [BEMA]
4,930,814_CD
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
8.2_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
._.
The_DT
shares_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
of_PIN
2.2_CD
million_CD
._.
Cade_NN
Struktur_NN
Corp._NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
total_JJ
SkyePharma_NN
holding_GER
of_PIN
Cade_NN
Struktur_NN
Corp._NN
a_DT
Canadian_JJ
company_NN
,_,
was_VBD [BEMA]
869,086_CD
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
16.8_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
._.
SkyePharma_NN
has_VPRT [PEAS]
not_XX0
attributed_VBN
a_DT
value_NN
to_PIN
these_DEMO
shares_NN
and_CC
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
at_PIN
zero_CD
cost_NN
._.
The_DT
shares_NN
were_VBD [SPAU] [PASS]
originally_TIME
acquired_VBN
consequent_JJ
upon_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
assets_NN
of_PIN
Hyal_NN
Pharmaceutical_NN
Corp._NN
._.
Other_JJ
investments_NOMZ
The_DT
Group_NN
has_VPRT
other_JJ
investments_NOMZ
of_PIN
4.0_CD
million_CD
in_PIN
a_DT
collaborative_JJ
partner_NN
based_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
,_,
representing_VBG [PRESP]
approximately_RB
14.2_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
,_,
recorded_VBN [PASTP]
at_PIN
Directors_NN
valuation_NOMZ
based_VBN [WZPAST]
on_PIN
a_DT
number_NN
of_PIN
considerations_NOMZ
including_VBG [WZPRES]
comparable_JJ
transactions_NOMZ
and_CC
discounted_JJ
future_JJ
cash_NN
flows_NN
._.
Own_JJ
shares_NN
During_PIN
2001_CD
the_DT
Company_NN
established_VBD [PRIV]
an_DT
employee_NN
share_NN
ownership_NN
trust_NN
,_,
the_DT
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
Trust_NN
._.
The_DT
purpose_NN
of_PIN
the_DT
trust_NN
is_VPRT
to_TO
hold_VB [PRIV]
shares_NN
in_PIN
the_DT
Company_NN
,_,
which_WDT [SERE]
may_POMD [SPAU]
subsequently_TIME
be_VB [PASS]
awarded_VBN
to_PIN
Directors_NN
and_PHC
employees_NN
under_IN
the_DT
Deferred_NN
Share_NN
Bonus_NN
Plan_NN
and_PHC
Share_NN
Purchase_NN
Plans_NN
._.
Further_JJ
details_NN
of_PIN
these_DEMO
plans_NN
are_VPRT [PASS]
described_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
During_PIN
the_DT
year_NN
,_,
the_DT
trust_NN
purchased_VBD
2_CD
million_CD
shares_NN
and_CC
893,415_CD
shares_NN
were_VBD [PASS]
allocated_VBN
at_PIN
an_DT
average_JJ
price_NN
of_PIN
66_CD
pence_NN
per_PIN
share_NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
the_DT
trust_NN
held_VBD [PRIV]
1,805,681_CD
shares_NN
at_PIN
a_DT
carrying_VBG
value_NN
of_PIN
1.0_CD
million_CD
and_CC
a_DT
market_NN
value_NN
of_PIN
0.7_CD
million_CD
._.
This_DEMO
shortfall_NN
is_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
represent_VB
a_DT
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
._.
b_NN
Company_NN
Shares_NN
in_PIN
Loans_NN
to_PIN
Group_NN
Group_NN
Unlisted_NN
Own_NN
undertakings_GER
undertakings_GER
investments_NOMZ
shares_NN
Total_JJ
000 000 000 000_CD
000_CD
At_PIN
1_CD
January_NN
2002_CD
203,847_CD
173,311_CD
7,481_CD
552_CD
385,191_CD
Additions_NOMZ
4,262_CD
8,000_CD
5,215_CD
1,070_CD
18,547_CD
Revaluation_NOMZ
of_PIN
shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
note_NN
23_CD
4,837_CD
4,837_CD
Lapse_NN
of_PIN
warrants_NN
1,096_CD
1,096_CD
Charge_NN
for_PIN
the_DT
year_NN
594_CD
594_CD
At_PIN
31_CD
December_NN
2002_CD
202,176_CD
181,311_CD
12,696_CD
1,028_CD
397,211_CD
65_CD
13_CD
Stock_NN
Group_NN
Group_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
919_CD
896_CD
Work_NN
in_PIN
progress_NN
263_CD
1,313_CD
Finished_VBN
goods_NN
74_CD
69_CD
1,256_CD
2,278_CD
The_DT
replacement_NOMZ
cost_NN
of_PIN
stock_NN
is_VPRT
not_XX0
materially_RB
different_PRED
from_PIN
original_JJ
cost_NN
._.
14_CD
Debtors_NN
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000 000_CD
000_CD
Trade_NN
debtors_NN
26,327_CD
8,662_CD
Amounts_NN
owed_VBN [WZPAST]
by_PIN
subsidiary_NN
undertakings_GER
24,310_CD
13,273_CD
Other_JJ
debtors_NN
2,224_CD
1,829_CD
122_CD
92_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
6,502_CD
3,515_CD
1,465_CD
673_CD
Interest_NN
receivable_NN
154_CD
16_CD
154_CD
16_CD
35,207_CD
14,022_CD
26,051_CD
14,054_CD
15_CD
Current_JJ
Asset_NN
Investments_NOMZ
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [BYPA]
represented_VBN
by_PIN
a_DT
convertible_JJ
loan_NN
note_VPRT [PRIV] [THATD]
the_DT
notes_NN
carrying_VBG [WZPRES]
a_DT
5_CD
%_NN
coupon_NN
,_,
due_JJ
at_PIN
par_NN
with_PIN
accrued_VBN
interest_NN
in_PIN
June_NN
2007_CD
._.
The_DT
notes_NN
were_VBD [PASS]
received_VBN
from_PIN
GeneMedix_NN
plc_NN
in_PIN
June_NN
2002_CD
as_IN
an_DT
initial_JJ
payment_NOMZ
under_IN
an_DT
agreement_NOMZ
to_TO [SPIN]
jointly_RB
develop_VB
an_DT
extended_JJ
release_NN
formulation_NOMZ
of_PIN
interferon_NN
alpha-2b_JJ
using_VBG
SkyePharmas_NN
DepoFoam_NN
technology_NN
._.
The_DT
notes_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
any_QUAN
time_NN
,_,
at_PIN
SkyePharmas_NN
option_NOMZ
,_,
into_PIN
between_PIN
approximately_RB
8.3_CD
million_CD
and_CC
11.2_CD
million_CD
GeneMedix_NN
ordinary_JJ
shares_NN
._.
There_EX
are_VPRT
no_SYNE
restrictions_NOMZ
or_CC
a_DT
lock-up_JJ
period_NN
on_PIN
conversion_NN
of_PIN
the_DT
notes_NN
._.
GeneMedix_NN
can_POMD
elect_VB
to_TO
redeem_VB
in_PIN
cash_NN
some_QUAN
or_CC
all_QUAN
of_PIN
the_DT
notes_NN
on_PIN
conversion_NN
under_IN
certain_JJ
circumstances_NN
._.
The_DT
notes_NN
have_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
._.
16_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000 000_CD
000_CD
Bank_NN
overdrafts_NN
1,618_CD
Bank_NN
loans_NN
1,572_CD
1,521_CD
Current_JJ
portion_NOMZ
of_PIN
secured_JJ
mortgage_NN
note_NN
17 270 248_CD
Current_JJ
portion_NOMZ
of_PIN
Chiron_NN
loan_NN
note_NN
3,023_CD
Trade_NN
creditors_NN
3,344_CD
3,716_CD
69_CD
260_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
subsidiary_NN
undertakings_GER
10,229_CD
4,553_CD
Corporation_NOMZ
tax_NN
3_CD
3_CD
Other_JJ
taxation_NOMZ
and_CC
social_JJ
security_NOMZ
costs_NN
893_CD
1,031_CD
83_CD
53_CD
Obligations_NOMZ
under_IN
hire_NN
purchase_NN
and_PHC
finance_NN
leases_NN
1,085_CD
847_CD
Deferred_JJ
income_NN
15,069_CD
11,690_CD
Accruals_NN
12,235_CD
11,491_CD
3,431_CD
3,467_CD
34,471_CD
35,188_CD
13,812_CD
8,333_CD
At_PIN
31_CD
December_NN
2002_CD
the_DT
Group_NN
had_VBD
loans_NN
with_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
of_PIN
0.9_CD
million_CD
CHF_NN
2_CD
million_CD
and_CC
0.7_CD
million_CD
CHF_NN
1.5_CD
million_CD
._.
These_DEMO
loans_NN
are_VPRT [BEMA]
renewable_JJ
annually_RB
and_CC
bear_VB
interest_NN
at_PIN
6.5_CD
%_NN
and_CC
6.0_CD
%_NN
respectively_RB
._.
The_DT
loans_NN
are_VPRT [PASS]
secured_VBN
on_PIN
the_DT
assets_NN
of_PIN
Jago_NN
and_CC
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
notes_NN
to_PIN
the_DT
financial_JJ
66_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
17_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000 000_CD
000_CD
Secured_JJ
mortgage_NN
7,502_CD
7,159_CD
Chiron_NN
promissory_JJ
note_NN
621_CD
Chiron_NN
loan_NN
note_NN
802_CD
Accrued_VBN
rent_NN
3,269_CD
3,385_CD
Convertible_JJ
bonds_NN
due_JJ
June_NN
2005_CD
58,377_CD
57,962_CD
58,377_CD
57,962_CD
Deferred_JJ
income_NN
2,960_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
235_CD
874_CD
72,964_CD
70,182_CD
58,377_CD
57,962_CD
Bank_NN
and_CC
other_JJ
loans_NN
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
5,158_CD
1,050_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
180_CD
4,179_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
180_CD
166_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
180_CD
166_CD
After_IN
five_CD
years_NN
2,425_CD
2,400_CD
8,123_CD
7,961_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
97_CD
843_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
55_CD
27_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
83_CD
4_CD
235_CD
874_CD
At_PIN
31_CD
December_NN
2002_CD
the_DT
Group_NN
had_VBD
a_DT
property_NN
mortgage_NN
facility_NOMZ
with_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
of_PIN
7.8_CD
million_CD
CHF_NN
17.3_CD
million_CD
of_PIN
which_WDT [PIRE]
0.3_CD
million_CD
CHF_NN
0.6_CD
million_CD
is_VPRT [PASS]
shown_VBN [PRIV]
within_PIN
current_JJ
liabilities_NOMZ
._.
The_DT
mortgage_NN
is_VPRT [BEMA]
in_PIN
two_CD
tranches_NN
,_,
both_DT
secured_VBN
by_PIN
the_DT
assets_NN
of_PIN
Jago_NN
and_CC
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
The_DT
first_JJ
tranche_NN
of_PIN
3.3_CD
million_CD
CHF_NN
7.4_CD
million_CD
bears_NN
interest_NN
at_PIN
4.25_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
over_IN
21_CD
years_NN
semi-annually_RB
._.
The_DT
second_JJ
tranche_NN
of_PIN
4.5_CD
million_CD
CHF_NN
9.9_CD
million_CD
bears_NN
interest_NN
at_PIN
3.0_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
in_PIN
2004_CD
._.
At_PIN
31_CD
December_NN
2002_CD
the_DT
Group_NN
had_VBD
a_DT
promissory_JJ
note_NN
with_PIN
Chiron_NN
of_PIN
0.6_CD
million_CD
$_$
1_CD
million_CD
which_WDT
formed_VBD
part_NN
of_PIN
the_DT
consideration_NOMZ
for_PIN
the_DT
reacquisition_NOMZ
of_PIN
the_DT
DepoCyt_NN
marketing_GER
,_,
distribution_NOMZ
and_PHC
sales_NN
rights_NN
._.
The_DT
promissory_JJ
note_NN
is_VPRT [BEMA]
repayable_PRED
in_PIN
2004_CD
and_CC
bears_VPRT
interest_NN
at_PIN
LIBOR_NN
plus_PIN
300_CD
points_NN
._.
It_PIT
is_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
The_DT
Chiron_NN
loan_NN
note_NN
was_VBD [PASS]
settled_VBN
during_PIN
the_DT
year_NN
._.
In_PIN
June_NN
2000_CD
,_,
the_DT
Company_NN
issued_VBN
59.4_CD
million_CD
6_CD
%_NN
Convertible_JJ
Bonds_NN
the_DT
Bonds_NN
due_JJ
2005_CD
._.
The_DT
Bonds_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
holder_NN
into_PIN
Ordinary_NN
Shares_NN
at_PIN
a_DT
conversion_NN
price_NN
of_PIN
83_CD
pence_NN
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
19_CD
June_NN
2005_CD
._.
Unless_COND
previously_TIME
redeemed_VBN
or_CC
converted_VBN
,_,
the_DT
Bonds_NN
will_PRMD
be_VB [BYPA]
redeemed_VBN
by_PIN
the_DT
Company_NN
at_PIN
their_TPP3
principal_JJ
amount_NN
on_PIN
19_CD
June_NN
2005_CD
._.
67_CD
18_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
National_NN
Total_NN
Pension_NN
Insurance_NN
Total_NN
Group_NN
000 000 000_CD
At_PIN
1_CD
January_NN
2002_CD
51_CD
17_CD
68_CD
Exchange_NN
adjustments_NOMZ
22_CD
22_CD
Charged_VBN
in_PIN
the_DT
year_NN
128_CD
128_CD
Utilised_VBN
17_CD
17_CD
At_PIN
31_CD
December_NN
2002 201 201_CD
National_NN
Insurance_NN
Company_NN
000_CD
At_PIN
1_CD
January_NN
2002_CD
3_CD
Utilised_VBN
3_CD
At_PIN
31_CD
December_NN
2002_CD
Pension_NN
provision_NN
The_DT
pension_NN
provision_NN
relates_VPRT
to_PIN
the_DT
retirement_NOMZ
commitments_NOMZ
under_IN
a_DT
defined_VBN
benefit_NN
scheme_NN
for_PIN
SkyePharma_NN
Production_NOMZ
SAS_NN
employees_NN
note_VPRT [PRIV]
26_CD
:_:
Pension_NN
Arrangements_NOMZ
._.
National_NN
Insurance_NN
provision_NN
A_DT
balance_NN
sheet_NN
provision_NN
of_PIN
Nil_NN
31_CD
December_NN
2001_CD
:_:
17,000_CD
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
accordance_NN
with_PIN
UITF25_NN
:_:
National_NN
Insurance_NN
contributions_NOMZ
on_PIN
share_NN
option_NOMZ
gains_NN
._.
19_CD
Deferred_JJ
taxation_NOMZ
Group_NN
Full_NN
potential_JJ
Company_NN
Full_NN
potential_JJ
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000 000_CD
000_CD
Accelerated_VBN
capital_NN
allowances_NN
4,848_CD
4,030_CD
42_CD
36_CD
Other_JJ
timing_NN
differences_NN
6,866_CD
10,891_CD
17_CD
14_CD
UK_NN
tax_NN
benefits_NN
from_PIN
losses_NN
carried_VBD
forward_RB
1,288_CD
1,893_CD
1,288_CD
1,893_CD
Overseas_PLACE
tax_NN
benefits_NN
from_PIN
losses_NN
carried_VBD
forward_RB
29,731_CD
31,480_CD
Potential_JJ
deferred_JJ
tax_NN
asset_NN
42,733_CD
48,294_CD
1,347_CD
1,943_CD
No_DT
deferred_VBN
tax_NN
asset_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
,_,
given_VBN
the_DT
uncertainty_NN
of_PIN
the_DT
recoverability_NOMZ
of_PIN
the_DT
Groups_NN
tax_NN
losses_NN
carried_VBD
forward_RB
._.
20_CD
Contingent_JJ
liabilities_NOMZ
and_PHC
guarantees_NN
At_PIN
31_CD
December_NN
2002_CD
the_DT
Company_NN
had_VBD [PEAS]
provided_VBN
guarantees_NN
on_PIN
various_JJ
bank_NN
borrowings_GER
of_PIN
its_PIT
subsidiaries_NN
as_IN
set_VBN
out_PIN
in_PIN
note_NN
16_CD
:_:
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
and_PHC
note_NN
17_CD
:_:
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
._.
In_PIN
December_NN
1999_CD
SkyePharma_NN
Production_NOMZ
SAS_NN
entered_VBD
into_PIN
a_DT
leasing_GER
arrangement_NOMZ
with_PIN
Lombard_NN
North_NN
Central_NN
PLC_NN
by_PIN
which_WDT [PIRE]
certain_JJ
pharmaceutical_JJ
manufacturing_GER
and_PHC
laboratory_NN
equipment_NOMZ
was_VBD [BEMA]
the_DT
subject_NN
of_PIN
a_DT
four-year_JJ
sale_NN
and_PHC
leaseback_NN
arrangement_NOMZ
._.
The_DT
Company_NN
has_VPRT [PEAS]
guaranteed_VBN [PUBV]
the_DT
obligations_NOMZ
of_PIN
the_DT
lessee_NN
under_IN
this_DEMO
lease_NN
to_PIN
an_DT
amount_NN
of_PIN
3.0_CD
million_CD
a4_JJ
.6_CD
million_CD
._.
In_PIN
common_JJ
with_PIN
most_EMPH
business_NOMZ
enterprises_NN
,_,
Group_NN
companies_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
number_NN
of_PIN
claims_NN
from_PIN
third_JJ
parties_NN
,_,
the_DT
outcome_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
at_PIN
present_JJ
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
but_CC
which_WDT
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB
material_NN
in_PIN
the_DT
context_NN
of_PIN
these_DEMO
Financial_NN
Statements_NOMZ
._.
Provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
these_DEMO
accounts_NN
for_PIN
any_QUAN
liabilities_NOMZ
which_WDT [WHSUB]
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
materialise_VB
from_PIN
such_JJ
claims_NN
._.
notes_NN
to_PIN
the_DT
financial_JJ
68_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
21_CD
Commitments_NOMZ
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000 000_CD
000_CD
Capital_NN
commitments_NOMZ
Contracted_VBN [WZPAST]
for_PIN
but_CC
not_XX0
provided_VBN
in_PIN
the_DT
accounts_NN
197_CD
340_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
for_PIN
the_DT
next_JJ
year_NN
Operating_VBG [WZPRES]
leases_NN
on_PIN
land_NN
and_PHC
buildings_GER
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
50_CD
187_CD
28_CD
21_CD
In_PIN
two_CD
to_PIN
five_CD
years_NN
707_CD
1,304_CD
566_CD
559_CD
In_PIN
five_CD
years_NN
or_CC
more_EMPH
1,816_CD
2,532_CD
2,573_CD
4,023_CD
594_CD
580_CD
Other_JJ
operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
18_CD
42_CD
5_CD
In_PIN
two_CD
to_PIN
five_CD
years_NN
53_CD
47_CD
11_CD
17_CD
In_PIN
five_CD
years_NN
or_CC
more_EMPH
2_CD
71_CD
91_CD
16_CD
17_CD
22_CD
Share_NN
capital_NN
Equity_NOMZ
share_NN
capital_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
000_CD
000_CD
Authorised_NN
Ordinary_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
1,114,000,000_CD
1,114,000,000_CD
111,400_CD
111,400_CD
Ordinary_NN
shares_NN
of_PIN
10p_JJ
each_QUAN
Nominal_JJ
value_NN
Number_NN
000_CD
Issued_VBN
,_,
allotted_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2001_CD
517,322,768_CD
51,732_CD
Exercise_NN
of_PIN
B_NN
Warrants_NN
22,008_CD
2_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
736,644_CD
74_CD
Exercise_NN
of_PIN
DepoTech_NN
Warrants_NN
41,820_CD
4_CD
Shares_NN
issued_VBN
to_TO
acquire_VB
RTP_NN
Pharma_NN
Inc._NN
41,900,099_CD
4,190_CD
At_PIN
31_CD
December_NN
2001_CD
560,023,339_CD
56,002_CD
Exercise_NN
of_PIN
B_NN
Warrants_NN
2,051,607_CD
205_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
1,323,853_CD
133_CD
Shares_NN
allocated_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
RTP_NN
Pharma_NN
Inc._NN
8,059,268_CD
806_CD
Issue_NN
of_PIN
shares_NN
to_PIN
Kowa_NN
Company_NN
Limited_NN
30,000,000_CD
3,000_CD
Conversion_NN
of_PIN
Deferred_NN
A_NN
Shares_NN
12,000,000_CD
1,200_CD
At_PIN
31_CD
December_NN
2002_CD
613,458,067_CD
61,346_CD
SkyePharma_NN
achieved_VBD
control_NN
of_PIN
RTP_NN
Pharma_NN
Inc._NN
in_PIN
December_NN
2001_CD
when_RB
agreement_NOMZ
was_VBD [PASS]
reached_VBN
to_TO
acquire_VB
the_DT
majority_NOMZ
of_PIN
the_DT
outstanding_JJ
voting_NN
shares_NN
in_PIN
RTP_NN
._.
In_PIN
March_NN
2002_CD
SkyePharma_NN
announced_VBD [PUBV]
the_DT
acquisition_NOMZ
of_PIN
the_DT
outstanding_JJ
voting_NN
shares_NN
in_PIN
RTP_NN
in_PIN
return_NN
for_PIN
the_DT
issue_NN
of_PIN
SkyePharma_NN
Ordinary_NN
Shares_NN
._.
The_DT
total_JJ
consideration_NOMZ
of_PIN
39.4_CD
million_CD
including_VBG
acquisition_NOMZ
costs_NN
comprised_VBD
49,959,367_CD
Ordinary_NN
Shares_NN
and_CC
4.1_CD
million_CD
cash_NN
._.
69_CD
22_CD
Share_NN
capital_NN
continued_VBD
The_DT
cash_NN
consideration_NOMZ
received_VBN [WZPAST]
on_PIN
the_DT
issue_NN
of_PIN
Ordinary_NN
Shares_NN
during_PIN
the_DT
year_NN
amounted_VBD
to_PIN
26,168,000_CD
2001_CD
:_:
468,000_CD
._.
Of_PIN
this_DEMP
,_,
30_CD
million_CD
Ordinary_NN
Shares_NN
were_VBD [PASS]
allotted_VBN
to_PIN
Kowa_NN
Company_NN
Limited_NN
for_PIN
a_DT
total_JJ
consideration_NOMZ
of_PIN
25.3_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
US_FPP1
launch_NN
and_CC
first_JJ
commercial_JJ
sale_NN
of_PIN
Paxil_NN
CR_NN
by_PIN
GlaxoSmithKline_NN
in_PIN
April_NN
2002_CD
,_,
the_DT
12_CD
million_CD
Deferred_NN
A_NN
Shares_NN
were_VBD [PASS]
converted_VBN
into_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
._.
Non-equity_JJ
share_NN
capital_NN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
000_CD
000_CD
Authorised_VBN
and_PHC
issued_VBN
Deferred_NN
A_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
12,000,000_CD
1,200_CD
Deferred_JJ
B_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
12,000,000_CD
12,000,000_CD
1,200_CD
1,200_CD
12,000,000_CD
24,000,000_CD
1,200_CD
2,400_CD
The_DT
Deferred_JJ
A_DT
and_CC
B_NN
Shares_NN
were_VBD [PASS]
issued_VBN
to_PIN
Dr_NN
Gonella_NN
,_,
the_DT
vendor_NN
of_PIN
Jago_NN
,_,
on_PIN
20_CD
July_NN
2000_CD
under_IN
the_DT
Settlement_NOMZ
Agreement_NOMZ
that_TSUB
established_VBD [PRIV]
the_DT
full_JJ
and_PHC
final_JJ
settlement_NOMZ
of_PIN
the_DT
deferred_JJ
consideration_NOMZ
payable_JJ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
._.
The_DT
holders_NN
of_PIN
Deferred_NN
A_NN
and_PHC
B_NN
Shares_NN
have_VPRT
no_SYNE
rights_NN
to_TO
participate_VB
in_PIN
the_DT
profits_NN
of_PIN
the_DT
Company_NN
,_,
no_SYNE
voting_NN
rights_NN
and_CC
on_PIN
a_DT
winding_VBG
up_RP
or_CC
other_JJ
return_NN
of_PIN
capital_NN
only_DWNT
receive_VB
the_DT
nominal_JJ
value_NN
of_PIN
their_TPP3
shares_NN
if_COND
the_DT
holders_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
the_DT
capital_NN
of_PIN
the_DT
Company_NN
have_VPRT [PEAS]
received_VBN
the_DT
sum_NN
of_PIN
1,000,000_CD
per_PIN
Ordinary_NN
Share_NN
and_CC
,_,
as_IN
such_JJ
,_,
are_VPRT [PASS]
classified_VBN
as_IN
non-equity_JJ
shares_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
Settlement_NOMZ
Agreement_NOMZ
,_,
following_VBG [PRESP]
the_DT
US_FPP1
launch_NN
and_CC
first_JJ
commercial_JJ
sale_NN
of_PIN
Paxil_NN
CR_NN
by_PIN
GlaxoSmithKline_NN
in_PIN
April_NN
2002_CD
,_,
the_DT
12_CD
million_CD
Deferred_NN
A_NN
Shares_NN
were_VBD [SPAU] [PASS]
automatically_RB
converted_VBN
into_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
._.
The_DT
12_CD
million_CD
Deferred_NN
B_NN
Shares_NN
automatically_RB
convert_VPRT
to_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
on_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
a_DT
royalty_NN
statement_NOMZ
under_IN
the_DT
current_JJ
Licence_NN
Agreement_NOMZ
stating_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
reported_VBD [PUBV]
sales_NN
of_PIN
Paroxetine_NN
Paxil_NN
in_PIN
combination_NOMZ
with_PIN
the_DT
GEOMATRIX_NN
technology_NN
have_VPRT [PEAS]
exceeded_VBN
$_$
1,000_CD
million_CD
during_PIN
any_QUAN
calendar_NN
period_NN
prior_RB
to_PIN
1_CD
January_NN
2006_CD
or_CC
exceeded_VBD
$_$
337_CD
million_CD
between_PIN
1_CD
January_NN
2006_CD
and_CC
3_CD
May_POMD
2006_CD
._.
In_PIN
the_DT
event_NN
that_DEMP
this_DEMO
condition_NOMZ
is_VPRT [BEMA]
not_XX0
satisfied_JJ
prior_RB
to_PIN
3_CD
May_POMD
2006_CD
,_,
the_DT
Deferred_NN
B_NN
Shares_NN
will_PRMD
not_XX0
be_VB [PASS]
converted_VBN
and_CC
will_PRMD
be_VB [PASS]
canceled_VBN
._.
The_DT
vendor_NN
will_PRMD
not_XX0
be_VB [PASS]
entitled_VBN
to_PIN
any_QUAN
other_JJ
compensation_NOMZ
nor_SYNE
additional_JJ
compensation_NOMZ
._.
The_DT
Deferred_JJ
A_DT
and_CC
B_NN
Shares_NN
were_VBD [PASS]
issued_VBN
on_PIN
20_CD
July_NN
2000_CD
when_RB
the_DT
price_NN
of_PIN
an_DT
Ordinary_NN
Share_NN
was_VBD [BEMA]
94.25_CD
pence_NN
._.
The_DT
difference_NN
between_PIN
the_DT
nominal_JJ
value_NN
of_PIN
the_DT
Deferred_NN
B_NN
Shares_NN
and_CC
their_TPP3
fair_JJ
value_NN
,_,
taken_VBN
to_TO
be_VB [BEMA]
94.25_CD
pence_NN
,_,
at_PIN
issue_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
as_IN
non-equity_JJ
share_NN
premium_NN
._.
Warrants_NN
The_DT
Company_NN
has_VPRT
the_DT
following_JJ
warrants_NN
outstanding_JJ
:_:
a_DT
B_NN
Warrants_NN
Number_NN
At_PIN
1_CD
January_NN
2002_CD
56,525,415_CD
Warrants_NN
exercised_VBN
20,516,073_CD
Warrants_NN
lapsed_VBD
36,009,342_CD
At_PIN
31_CD
December_NN
2002_CD
The_DT
B_NN
Warrants_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
issued_VBN
in_PIN
January_NN
1996_CD
on_PIN
the_DT
basis_NN
of_PIN
one_CD
warrant_NN
for_PIN
every_QUAN
ten_NN
existing_VBG [WZPRES]
Ordinary_NN
Shares_NN
subscribed_VBD
pursuant_JJ
to_PIN
the_DT
placing_GER
,_,
rights_NN
issue_NN
and_PHC
capitalization_NOMZ
of_PIN
loan_NN
notes_NN
and_CC
in_PIN
consideration_NOMZ
for_PIN
the_DT
outstanding_JJ
warrants_NN
of_PIN
Krypton_NN
,_,
entitled_VBD
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
beginning_VBG [WZPRES]
six_CD
months_NN
after_IN
the_DT
date_NN
of_PIN
issue_NN
and_CC
ending_VBG
on_PIN
31_CD
December_NN
2002_CD
at_PIN
an_DT
effective_JJ
price_NN
of_PIN
40_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
based_VBN [WZPAST]
on_PIN
ten_JJ
warrants_NN
._.
Consequent_JJ
upon_PIN
the_DT
consolidation_NOMZ
of_PIN
existing_VBG
Ordinary_NN
Shares_NN
in_PIN
May_POMD
1996_CD
the_DT
terms_NN
under_IN
which_WDT
the_DT
B_NN
Warrants_NN
may_POMD
be_VB [PASS]
exercised_VBN
were_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
a_DT
holder_NN
was_VBD [PASS]
required_VBN [SUAV]
to_TO
exercise_VB
ten_NN
B_NN
Warrants_NN
to_TO
acquire_VB
one_CD
Ordinary_NN
Share_NN
._.
All_QUAN
outstanding_JJ
B_NN
Warrants_NN
lapsed_VBD
on_PIN
31_CD
December_NN
2002_CD
and_CC
so_RB
the_DT
market_NN
value_NN
of_PIN
B_NN
Warrants_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
was_VBD [BEMA]
nil_CD
pence_NN
31_CD
December_NN
2001_CD
:_:
3.25_CD
pence_NN
._.
The_DT
market_NN
value_NN
of_PIN
B_NN
Warrants_NN
during_PIN
the_DT
period_NN
from_PIN
1_CD
January_NN
2002_CD
to_PIN
31_CD
December_NN
2002_CD
ranged_VBD
from_PIN
the_DT
lowest_JJ
mid-price_NN
of_PIN
nil_NN
pence_NN
to_PIN
the_DT
highest_JJ
mid-price_NN
of_PIN
4.75_CD
pence_NN
per_PIN
B_NN
Warrant_NN
._.
notes_NN
to_PIN
the_DT
financial_JJ
70_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
22_CD
Share_NN
capital_NN
continued_VBD
b_NN
D_NN
and_PHC
E_NN
Warrants_NN
The_DT
D_NN
and_PHC
E_NN
Warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
March_NN
2002_CD
as_IN
part_NN
of_PIN
the_DT
consideration_NOMZ
for_PIN
the_DT
agreement_NOMZ
with_PIN
Paul_NN
Capital_NN
to_TO
fund_VB
new_JJ
product_NN
development_NOMZ
._.
The_DT
D_NN
and_PHC
E_NN
Warrants_NN
entitle_VPRT
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
a_DT
total_NN
of_PIN
5_CD
million_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
to_PIN
31_CD
December_NN
2008_CD
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
73.75_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
._.
A_DT
value_NN
of_PIN
0.3_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
attributed_VBN
to_PIN
the_DT
D_NN
and_PHC
E_NN
Warrants_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
within_PIN
Other_JJ
Reserves_NN
._.
c_NN
Other_JJ
Warrants_NN
Warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
December_NN
1999_CD
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
DepoTech_NN
and_CC
entitle_VB
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
291,777_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
beginning_VBG [WZPRES]
31_CD
December_NN
1999_CD
and_CC
ending_VBG
on_PIN
25_CD
February_NN
2005_CD
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
$_$
1.453_CD
90.25_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
._.
Share_NN
options_NOMZ
The_DT
Company_NN
encourages_VPRT
employee_NN
participation_NOMZ
in_PIN
its_PIT
shares_NN
through_PIN
ownership_NN
and_CC
continues_VPRT
to_TO
operate_VB
various_JJ
Share_NN
Option_NOMZ
Schemes_NN
and_CC
the_DT
Unapproved_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
these_DEMO
Schemes_NN
the_DT
Board_NN
may_POMD
offer_VB
options_NOMZ
to_TO
purchase_VB
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
to_PIN
employees_NN
,_,
including_VBG
Directors_NN
,_,
at_PIN
a_DT
price_NN
not_XX0
less_JJ
than_PIN
the_DT
higher_JJ
of_PIN
the_DT
nominal_JJ
value_NN
and_CC
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
UK_NN
and_CC
European_JJ
employees_NN
are_VPRT [BEMA]
only_DWNT
exercisable_PRED
between_PIN
the_DT
third_JJ
and_CC
tenth_NN
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
,_,
and_ANDC
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Companys_NN
Code_NN
of_PIN
Conduct_NN
for_PIN
dealing_VBG
in_PIN
Shares_NN
,_,
and_ANDC
the_DT
Model_NN
Code_NN
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
US_FPP1
employees_NN
prior_RB
to_PIN
2001_CD
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
there_EX
were_VBD
no_SYNE
performance_NN
criteria_NN
._.
UK_NN
and_CC
European_JJ
options_NOMZ
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
exercised_VBN
if_COND
the_DT
growth_NN
in_PIN
the_DT
Companys_NN
share_NN
price_NN
over_IN
a_DT
consecutive_JJ
three-year_JJ
period_NN
exceeds_VPRT
the_DT
growth_NN
over_IN
the_DT
same_JJ
period_NN
in_PIN
the_DT
FT-SE_NN
All_QUAN
Share_NN
Index_NN
for_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
2001_CD
._.
This_DEMO
criteria_NN
was_VBD [PASS]
satisfied_VBN
for_PIN
the_DT
first_JJ
time_NN
in_PIN
March_NN
2000_CD
._.
Employees_NN
with_PIN
options_NOMZ
that_TSUB
are_VPRT [BEMA]
within_PIN
their_TPP3
exercise_NN
period_NN
are_VPRT [BEMA]
now_TIME
able_PRED
to_TO
exercise_VB
those_DEMO
options_NOMZ
within_PIN
any_QUAN
one-year_JJ
period_NN
from_PIN
the_DT
date_NN
the_DT
performance_NN
condition_NOMZ
is_VPRT [PASS]
satisfied_VBN
._.
Super_NN
Options_NOMZ
are_VPRT [BEMA]
exercisable_PRED
after_IN
five_CD
years_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
higher_JJ
performance_NN
conditions_NOMZ
in_PIN
accordance_NN
with_PIN
those_DEMP
recommended_VBN [SUAV]
by_PIN
the_DT
Association_NOMZ
of_PIN
British_NN
Insurers_NN
._.
Following_VBG
changes_NN
to_PIN
the_DT
option_NOMZ
plans_VPRT
approved_VBN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
June_NN
2001_CD
,_,
options_NOMZ
granted_VBD [SUAV]
since_OSUB
that_DEMO
date_NN
to_PIN
Directors_NN
and_CC
senior_JJ
employees_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
total_JJ
shareholder_NN
return_NN
of_PIN
a_DT
comparator_NN
group_NN
of_PIN
companies_NN
,_,
and_ANDC
are_VPRT [BEMA]
not_XX0
subject_PRED
to_TO
retesting_VBG
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
other_JJ
US_FPP1
employees_NN
continue_VPRT
to_PIN
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
with_PIN
no_SYNE
performance_NN
criteria_NN
,_,
and_ANDC
other_JJ
European_JJ
employees_NN
who_WP [WHSUB]
are_VPRT
not_XX0
Directors_NN
or_CC
senior_JJ
employees_NN
can_POMD
exercise_VB
their_TPP3
options_NOMZ
after_IN
three_CD
years_NN
and_CC
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
._.
The_DT
Groups_NN
plans_NN
are_VPRT [BEMA]
further_PRED
detailed_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
The_DT
market_NN
value_NN
of_PIN
Ordinary_NN
Shares_NN
during_PIN
2002_CD
ranged_VBD
from_PIN
the_DT
lowest_JJ
closing_GER
mid-price_NN
of_PIN
39.0_CD
pence_NN
to_PIN
the_DT
highest_JJ
closing_GER
mid-price_NN
of_PIN
80.25_CD
pence_NN
per_PIN
share_NN
._.
71_CD
22_CD
Share_NN
capital_NN
continued_VBD
At_PIN
31_CD
December_NN
2002_CD
the_DT
following_VBG
Ordinary_NN
Shares_NN
were_VBD
under_IN
option_NOMZ
to_PIN
employees_NN
or_CC
former_JJ
employees_NN
of_PIN
the_DT
Group_NN
:_:
Option_NOMZ
price_NN
for_PIN
each_QUAN
Number_NN
of_PIN
options_NOMZ
over_IN
Ordinary_NN
Share_NN
of_PIN
10p_CD
Ordinary_NN
shares_NN
of_PIN
10p_CD
Expiry_NN
date_NN
75.0_CD
p_NN
1,427,676_CD
29_CD
April_NN
2006_CD
92.0_CD
p_NN
417,255_CD
28_CD
May_POMD
2006_CD
81.0_CD
p_NN
1,234,568_CD
6_CD
December_NN
2006_CD
66.5_CD
p_NN
646,281_CD
7_CD
April_NN
2007_CD
51.0_CD
p_NN
124,073_CD
28_CD
January_NN
2008_CD
93.0_CD
p_NN
796,362_CD
31_CD
March_NN
2008_CD
44.8_CD
p_NN
1,464,612_CD
5_CD
October_NN
2008_CD
69.5_CD
p_NN
3,232,813_CD
19_CD
April_NN
2009_CD
56.7_CD
p_NN
8,421,310_CD
25_CD
May_POMD
2009_CD
56.9_CD
p_NN
238,066_CD
7_CD
September_NN
2009_CD
91.3_CD
p_NN
1,036,268_CD
6_CD
June_NN
2010_CD
81.7_CD
p_NN
1,853,441_CD
3_CD
November_NN
2010_CD
80.6_CD
p_NN
6,602,439_CD
12_CD
June_NN
2011_CD
55.6_CD
p_NN
1,318,008_CD
31_CD
October_NN
2011_CD
55.1_CD
p_NN
552,514_CD
24_CD
December_NN
2011_CD
72.3_CD
p_NN
9,147,254_CD
12_CD
April_NN
2012_CD
78.6_CD
p_NN
515,653_CD
24_CD
May_POMD
2012_CD
51.7_CD
p_NN
1,428,340_CD
25_CD
September_NN
2012_CD
23_CD
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
Group_NN
and_PHC
Company_NN
000_CD
At_PIN
1_CD
January_NN
2002_CD
10,617_CD
Goodwill_NN
adjustments_NOMZ
on_PIN
deferred_JJ
consideration_NOMZ
4,837_CD
Shares_NN
allocated_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
RTP_NN
Pharma_NN
Inc._NN
5,780_CD
At_PIN
31_CD
December_NN
2002_CD
a_DT
Krypton_NN
The_NN
deferred_JJ
consideration_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Krypton_NN
was_VBD [PASS]
revised_VBN
in_PIN
April_NN
1996_CD
,_,
such_OSUB
that_NULL
a_DT
maximum_NN
of_PIN
37.5_CD
million_CD
Ordinary_NN
Shares_NN
would_PRMD
be_VB [PASS]
issued_VBN
contingent_NN
on_PIN
a_DT
change_NN
in_PIN
control_NN
of_PIN
the_DT
Company_NN
at_PIN
a_DT
share_NN
price_NN
of_PIN
not_XX0
less_JJ
than_PIN
80_CD
pence_NN
compounded_VBN [WZPAST]
at_PIN
an_DT
annual_JJ
rate_NN
of_PIN
10_CD
%_NN
,_,
or_CC
satisfaction_NOMZ
of_PIN
the_DT
following_JJ
conditions_NOMZ
and_PHC
hurdles_NN
:_:
i_FPP1
2.5_CD
million_CD
Ordinary_NN
Shares_NN
on_PIN
each_QUAN
Krypton_NN
product_NN
obtaining_VBG [WZPRES]
ANDA_NN
approval_NN
before_IN
31_CD
December_NN
2003_CD
,_,
subject_JJ
to_PIN
a_DT
maximum_NN
of_PIN
7.5_CD
million_CD
Ordinary_NN
shares_NN
._.
ii_FW
an_DT
additional_JJ
10_CD
million_CD
Ordinary_NN
Shares_NN
in_PIN
the_DT
event_NN
that_TOBJ
the_DT
aggregate_JJ
annual_JJ
sales_NN
of_PIN
the_DT
Krypton_NN
products_NN
exceeds_VPRT
$_$
50_CD
million_CD
and_CC
the_DT
Company_NN
is_VPRT [BEMA]
profitable_PRED
in_PIN
respect_NN
of_PIN
these_DEMO
products_NN
before_IN
31_CD
December_NN
2003_CD
:_:
iii_FW
an_DT
additional_JJ
10_CD
million_CD
Ordinary_NN
Shares_NN
in_PIN
the_DT
event_NN
that_TOBJ
the_DT
aggregate_JJ
annual_JJ
sales_NN
of_PIN
the_DT
Krypton_NN
products_NN
and_CC
annual_JJ
revenues_NN
of_PIN
the_DT
Company_NN
exceeds_VPRT
$_$
200_CD
million_CD
and_CC
the_DT
Company_NN
is_VPRT [BEMA]
profitable_PRED
in_PIN
respect_NN
of_PIN
these_DEMO
products_NN
before_IN
31_CD
December_NN
2003_CD
:_:
iv_VB
an_DT
additional_JJ
10_CD
million_CD
Ordinary_NN
Shares_NN
in_PIN
the_DT
event_NN
that_TOBJ
the_DT
aggregate_JJ
annual_JJ
sales_NN
of_PIN
the_DT
Krypton_NN
products_NN
and_CC
annual_JJ
revenues_NN
of_PIN
the_DT
Company_NN
exceeds_VPRT
$_$
275_CD
million_CD
and_CC
the_DT
Company_NN
is_VPRT [BEMA]
profitable_PRED
in_PIN
respect_NN
of_PIN
these_DEMO
products_NN
before_IN
31_CD
December_NN
2003_CD
._.
In_PIN
the_DT
event_NN
that_TOBJ
two_CD
of_PIN
hurdles_NN
ii_FW
,_,
iii_NN
and_PHC
iv_NN
are_VPRT [PASS]
satisfied_VBN
in_PIN
relation_NOMZ
to_PIN
any_QUAN
single_JJ
years_NN
sales_NN
,_,
only_DWNT
the_DT
first_JJ
such_JJ
hurdle_NN
will_PRMD
be_VB [PASS]
considered_VBN [PRIV]
as_IN
having_VBG [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
notes_NN
to_PIN
the_DT
financial_JJ
72_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
23_CD
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
continued_VBN
Certain_NN
of_PIN
the_DT
hurdles_NN
relating_VBG [WZPRES]
to_PIN
the_DT
Krypton_NN
acquisition_NOMZ
were_VBD [PASS]
not_XX0
formulated_VBN
to_TO
take_VB
account_NN
of_PIN
the_DT
detailed_JJ
arrangements_NOMZ
currently_RB
envisaged_VBN
by_PIN
the_DT
Company_NN
._.
Should_NEMD
the_DT
annual_JJ
revenues_NN
of_PIN
the_DT
Company_NN
approach_NN
the_DT
amounts_NN
specified_VBN [WZPAST]
in_PIN
hurdles_NN
iii_NN
and_PHC
iv_NN
,_,
SkyePharma_NN
may_POMD
need_VB
to_TO
renegotiate_VB
elements_NOMZ
of_PIN
the_DT
Krypton_NN
acquisition_NOMZ
agreement_NOMZ
._.
As_IN
no_SYNE
Krypton_NN
products_NN
are_VPRT [PASS]
marketed_VBN
and_CC
no_SYNE
licensing_GER
partners_NN
have_VPRT [PEAS]
been_VBN [PASS]
identified_VBN
for_PIN
the_DT
products_NN
the_DT
Directors_NN
have_VPRT [PEAS]
taken_VBN
the_DT
view_NN
that_TOBJ
the_DT
above_PLACE
hurdles_NN
can_POMD [SPAU]
no_RB
longer_RB
be_VB [SPAU] [PASS]
reasonably_RB
expected_VBN [PRIV]
to_TO
be_VB [PASS]
met_VBN
._.
Consequently_CONJ
no_SYNE
provision_NN
for_PIN
deferred_JJ
consideration_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
at_PIN
31_CD
December_NN
2002_CD
._.
b_NN
RTP_NN
As_IN
part_NN
of_PIN
the_DT
RTP_NN
acquisition_NOMZ
deferred_VBD
consideration_NOMZ
may_POMD
be_VB [BEMA]
due_PRED
to_PIN
the_DT
former_JJ
RTP_NN
shareholders_NN
in_PIN
consideration_NOMZ
for_PIN
the_DT
loss_NN
of_PIN
certain_JJ
option_NOMZ
rights_NN
._.
If_COND
the_DT
SkyePharma_NN
share_NN
price_NN
is_VPRT
below_PLACE
82_CD
pence_NN
on_PIN
30_CD
June_NN
2003_CD
,_,
then_RB
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
issue_VB
200,000_CD
additional_JJ
shares_NN
,_,
or_CC
pay_VB
an_DT
amount_NN
in_PIN
cash_NN
,_,
for_PIN
each_QUAN
penny_NN
difference_NN
between_PIN
the_DT
actual_JJ
share_NN
price_NN
and_CC
82_CD
pence_NN
._.
In_PIN
the_DT
opinion_NN
of_PIN
the_DT
Directors_NN
,_,
the_DT
outcome_NN
can_POMD
not_XX0
be_VB [PASS]
estimated_VBN [PRIV]
with_PIN
any_QUAN
degree_NN
of_PIN
certainty_NN
._.
Therefore_CONJ
this_DEMO
deferred_JJ
consideration_NOMZ
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
at_PIN
31_CD
December_NN
2002_CD
._.
c_NN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
In_PIN
March_NN
2002_CD
the_DT
Group_NN
announced_VBD [PUBV]
a_DT
second_JJ
transaction_NOMZ
with_PIN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
under_IN
which_WDT
SkyePharma_NN
will_PRMD
issue_VB
Ordinary_NN
Shares_NN
up_IN
to_PIN
a_DT
value_NN
of_PIN
$_$
7.5_CD
million_CD
if_COND
royalties_NN
and_PHC
milestones_NN
received_VBN [WZPAST]
by_PIN
SkyePharma_NN
in_PIN
respect_NN
of_PIN
those_DEMO
products_NN
included_VBD
in_PIN
the_DT
transaction_NOMZ
are_VPRT [BEMA]
not_XX0
in_PIN
excess_NN
of_PIN
minimum_JJ
annual_JJ
payments_NOMZ
required_VBN [SUAV]
to_TO
be_VB [BYPA]
made_VBN
by_PIN
Paul_NN
Capital_NN
._.
During_PIN
2002_CD
the_DT
royalties_NN
received_VBN [WZPAST]
by_PIN
SkyePharma_NN
were_VBD [BEMA]
substantially_RB
in_PIN
excess_NN
of_PIN
the_DT
minimum_JJ
payments_NOMZ
required_VBN [SUAV]
to_TO
be_VB [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
,_,
consequently_CONJ
the_DT
company_NN
has_VPRT [PEAS]
not_XX0
provided_VBN
for_PIN
any_QUAN
additional_JJ
obligations_NOMZ
under_IN
this_DEMO
provision_NN
._.
24_CD
Reserves_NN
Equity_NOMZ
Non-equity_NOMZ
Profit_NN
and_PHC
share_NN
share_NN
Other_JJ
loss_NN
premium_NN
premium_NN
reserves_NN
account_VPRT
Group_NN
000 000 000 000_CD
At_PIN
1_CD
January_NN
2002_CD
267,137_CD
20,220_CD
10,720_CD
271,951_CD
Exchange_NN
adjustments_NOMZ
903_CD
On_PIN
issue_NN
of_PIN
shares_NN
and_PHC
warrants_NN
37,366_CD
10,110_CD
311_CD
On_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
567_CD
On_PIN
exercise_NN
of_PIN
warrants_NN
1,239_CD
624_CD
On_PIN
lapse_NN
of_PIN
warrants_NN
1,096_CD
1,096_CD
Goodwill_NN
adjustments_NOMZ
on_PIN
deferred_JJ
consideration_NOMZ
4,837_CD
Profit_NN
for_PIN
the_DT
year_NN
1,109_CD
At_PIN
31_CD
December_NN
2002_CD
306,309_CD
10,110_CD
9,311_CD
264,006_CD
Other_JJ
reserves_NN
relate_VPRT
to_PIN
a_DT
merger_NN
reserve_NN
on_PIN
acquisition_NOMZ
and_CC
a_DT
warrant_NN
reserve_NN
on_PIN
the_DT
issue_NN
of_PIN
the_DT
D_NN
and_PHC
E_NN
Warrants_NN
._.
As_IN
at_PIN
31_CD
December_NN
2002_CD
the_DT
cumulative_JJ
amount_NN
of_PIN
goodwill_NN
eliminated_VBN [WZPAST]
against_PIN
reserves_NN
was_VBD [BEMA]
147,632,000_CD
2001_CD
:_:
152,469,000_CD
._.
Equity_NOMZ
Non-equity_NOMZ
Profit_NN
and_PHC
share_NN
share_NN
Other_JJ
loss_NN
premium_NN
premium_NN
reserves_NN
account_VPRT
Company_NN
000 000 000 000_CD
At_PIN
1_CD
January_NN
2002_CD
267,137_CD
20,220_CD
10,720_CD
16,494_CD
On_PIN
issue_NN
of_PIN
shares_NN
and_PHC
warrants_NN
37,366_CD
10,110_CD
311_CD
On_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
567_CD
On_PIN
exercise_NN
of_PIN
warrants_NN
1,239_CD
624_CD
On_PIN
lapse_NN
of_PIN
warrants_NN
1,096_CD
Profit_NN
for_PIN
the_DT
year_NN
146_CD
At_PIN
31_CD
December_NN
2002_CD
306,309_CD
10,110_CD
9,311_CD
16,348_CD
As_IN
permitted_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Profit_NN
and_PHC
Loss_NN
Account_NN
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
._.
The_DT
profit_NN
attributable_JJ
to_PIN
shareholders_NN
dealt_VBN [WZPAST]
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
is_VPRT [BEMA]
146,000_CD
2001_CD
:_:
1,269,000_CD
._.
73_CD
25_CD
Financial_NN
instruments_NOMZ
The_DT
Group_NN
holds_VPRT [PRIV]
financial_JJ
instruments_NOMZ
to_TO
finance_VB
its_PIT
operations_NOMZ
and_CC
to_TO
manage_VB
the_DT
currency_NN
risk_NN
that_TSUB
arises_VPRT
from_PIN
these_DEMO
operations_NOMZ
._.
The_DT
Group_NN
finances_VPRT
its_PIT
operations_NOMZ
through_PIN
a_DT
combination_NOMZ
of_PIN
shareholders_NN
funds_NN
,_,
convertible_JJ
bonds_NN
,_,
bank_NN
loans_NN
and_CC
other_JJ
borrowings_GER
._.
The_DT
main_JJ
risks_NN
arising_VBG [WZPRES]
from_PIN
the_DT
groups_NN
financial_JJ
instruments_NOMZ
are_VPRT
liquidity_NOMZ
risk_NN
,_,
foreign_JJ
currency_NN
risk_NN
,_,
interest_NN
rate_NN
risk_NN
and_PHC
credit_NN
risk_NN
._.
Liquidity_NOMZ
risks_NN
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
maintain_VB [PUBV]
continuity_NOMZ
of_PIN
funding_VBG
through_PIN
a_DT
mixture_NN
of_PIN
long-term_JJ
debt_NN
and_PHC
bank_NN
loans_NN
,_,
raised_VBD
to_TO
cover_VB
specific_JJ
projects_NN
,_,
and_ANDC
through_PIN
the_DT
issue_NN
of_PIN
shares_NN
to_PIN
collaborative_JJ
partners_NN
,_,
where_RB
necessary_JJ
,_,
to_TO
finance_VB
development_NOMZ
contracts_NN
._.
Short-term_JJ
flexibility_NOMZ
is_VPRT [PASS]
provided_VBN
through_PIN
the_DT
use_NN
of_PIN
overdrafts_NN
._.
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
debt_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
at_PIN
note_NN
c._NN
Foreign_JJ
currency_NN
risk_NN
All_QUAN
of_PIN
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
based_VBN
overseas_PLACE
in_PIN
Continental_NN
Europe_NN
and_PHC
North_NN
America_NN
giving_VBG [WZPRES]
rise_NN
to_PIN
exposures_NN
to_PIN
changes_NN
in_PIN
foreign_JJ
exchange_NN
rates_NN
notably_RB
the_DT
Swiss_JJ
Franc_NN
,_,
Euro_NN
,_,
Swedish_NN
Krona_NN
,_,
US_FPP1
Dollar_NN
and_PHC
Canadian_NN
Dollar_NN
._.
To_TO
minimize_VB
the_DT
impact_NN
of_PIN
any_QUAN
fluctuations_NOMZ
,_,
the_DT
Groups_NN
policy_NN
has_VPRT [SPAU] [PEAS]
historically_RB
been_VBN
to_TO
maintain_VB [PUBV]
natural_JJ
hedges_NN
by_PIN
relating_VBG
the_DT
structure_NN
of_PIN
borrowings_GER
to_PIN
the_DT
trading_GER
cash_NN
flows_VPRT
that_DEMP
generate_VB
them_TPP3
._.
Where_RB
subsidiaries_NN
are_VPRT [PASS]
funded_VBN
centrally_RB
,_,
this_DEMP
is_VPRT [BYPA]
achieved_VBN
by_PIN
the_DT
use_NN
of_PIN
long-term_JJ
loans_NN
the_DT
exchange_NN
differences_NN
on_PIN
which_WDT [PIRE]
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
._.
Where_RB
it_PIT
was_VBD [BEMA]
not_XX0
possible_PRED
to_TO
use_VB
natural_JJ
hedges_NN
,_,
currency_NN
options_NOMZ
,_,
accrual_NN
forward_RB
options_NOMZ
and_CC
forward_JJ
currency_NN
contracts_NN
were_VBD [PASS]
used_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
used_VBN
these_DEMO
financial_JJ
instruments_NOMZ
during_PIN
the_DT
year_NN
to_TO
minimize_VB
the_DT
currency_NN
exposure_NN
on_PIN
operational_JJ
transactions_NOMZ
._.
Foreign_JJ
currency_NN
exchange_NN
movements_NOMZ
did_VBD
not_XX0
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
results_NN
of_PIN
operations_NOMZ
in_PIN
2002_CD
compared_VBN
with_PIN
2001_CD
._.
Interest_NN
rate_NN
risk_NN
The_DT
Group_NN
borrows_VPRT
at_PIN
fixed_VBN
and_PHC
floating_VBG
rates_NN
of_PIN
interest_NN
as_IN
deemed_VBN [PRIV]
appropriate_JJ
for_PIN
its_PIT
circumstances_NN
._.
Where_RB
necessary_JJ
the_DT
Group_NN
uses_VPRT
several_QUAN
interest_NN
rate_NN
swaps_NN
to_TO
achieve_VB
the_DT
desired_VBN [SUAV]
interest_NN
rate_NN
profile_NN
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
had_VBD
several_QUAN
cancellable_JJ
,_,
floating_VBG
rate_NN
,_,
interest_NN
rate_NN
swaps_NN
on_PIN
30_CD
million_CD
of_PIN
the_DT
6_CD
%_NN
convertible_JJ
bond_NN
liability_NOMZ
._.
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
notes_NN
a_DT
and_CC
b_NN
respectively_RB
._.
Credit_NN
risk_NN
The_NN
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
credit_NN
related_VBN
losses_NN
in_PIN
the_DT
event_NN
of_PIN
non-performance_JJ
by_PIN
third_JJ
parties_NN
to_PIN
financial_JJ
instruments_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
any_QUAN
third_JJ
parties_NN
to_TO
fail_VB
to_TO
meet_VB
their_TPP3
obligations_NOMZ
given_VBN
the_DT
policy_NN
of_PIN
selecting_VBG
only_DWNT
parties_NN
with_PIN
high_JJ
credit_NN
ratings_GER
and_CC
minimizing_VBG
its_PIT
exposure_NN
to_PIN
any_QUAN
one_CD
institution_NOMZ
._.
In_PIN
the_DT
numerical_JJ
disclosures_NN
that_TSUB
follow_VPRT
,_,
short-term_JJ
debtors_NN
and_PHC
creditors_NN
that_TSUB
arise_VPRT
directly_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
excluded_VBN
from_PIN
all_QUAN
disclosures_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
note_NN
f_SYM
on_PIN
currency_NN
exposures_NN
._.
a_DT
Interest_NN
rate_NN
and_PHC
currency_NN
profile_NN
of_PIN
financial_JJ
assets_NN
31_CD
December_NN
2002_CD
Non-interest_JJ
Floating_VBG
rate_NN
Fixed_VBN
rate_NN
bearing_VBG [WZPRES]
Total_JJ
financial_JJ
financial_JJ
assets_NN
financial_JJ
assets_NN
financial_JJ
assets_NN
assets_NN
Currency_NN
000 000 000 000_CD
Sterling_GER
18,680_CD
1,961_CD
36_CD
20,677_CD
$_$
US_FPP1
4,292_CD
16,663_CD
20,955_CD
Swiss_JJ
francs_NN
1,870_CD
1,870_CD
$_$
Canadian_JJ
2,026_CD
2,228_CD
4,254_CD
Euro_NN
617_CD
617_CD
Swedish_NN
Krona_NN
523_CD
523_CD
28,008_CD
1,961_CD
18,927_CD
48,896_CD
Total_JJ
financial_JJ
assets_NN
comprise_VPRT
fixed_VBN
asset_NN
investments_NOMZ
of_PIN
18.9_CD
million_CD
2001_CD
:_:
13.7_CD
million_CD
,_,
current_JJ
asset_NN
investments_NOMZ
of_PIN
2.0_CD
million_CD
2001_CD
:_:
nil_NN
and_PHC
cash_NN
and_CC
short-term_JJ
bank_NN
deposits_NN
of_PIN
28.1_CD
million_CD
2001_CD
:_:
26.9_CD
million_CD
._.
Floating_VBG
rate_NN
financial_JJ
assets_NN
bear_VPRT
interest_NN
at_PIN
rates_NN
based_VBN [WZPAST]
upon_PIN
the_DT
floating_VBG
bank_NN
rate_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
funds_NN
are_VPRT [PASS]
held_VBN [PRIV]
._.
The_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
on_PIN
fixed_JJ
rate_NN
financial_JJ
assets_NN
is_VPRT [BEMA]
5_CD
%_NN
2001_CD
:_:
2_CD
%_NN
._.
The_DT
weighted_JJ
average_JJ
time_NN
for_PIN
which_WDT [PIRE]
the_DT
rate_NN
is_VPRT [PASS]
fixed_VBN
is_VPRT [BEMA]
54_CD
months_NN
2001_CD
:_:
4_CD
months_NN
._.
notes_NN
to_PIN
the_DT
financial_JJ
74_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
31_CD
December_NN
2001_CD
Non-interest_JJ
Floating_VBG
rate_NN
Fixed_VBN
rate_NN
bearing_VBG [WZPRES]
Total_JJ
financial_JJ
financial_JJ
assets_NN
financial_JJ
assets_NN
financial_JJ
assets_NN
assets_NN
Currency_NN
000 000 000 000_CD
Sterling_GER
5,690_CD
62_CD
5,752_CD
$_$
US_FPP1
14,977_CD
11,467_CD
26,444_CD
Swiss_JJ
francs_NN
549_CD
93_CD
642_CD
$_$
Canadian_JJ
48_CD
5,389_CD
2,228_CD
7,665_CD
Euro_NN
48_CD
48_CD
21,312_CD
5,389_CD
13,850_CD
40,551_CD
b_NN
Interest_NN
rate_NN
and_PHC
currency_NN
profile_NN
of_PIN
financial_JJ
liabilities_NOMZ
Weighted_VBN
average_JJ
31_CD
December_NN
2002_CD
interest_NN
rate_NN
Weighted_JJ
Non-interest_JJ
Fixed_JJ
rate_NN
on_PIN
fixed_VBN
average_JJ
time_NN
Floating_VBG [WZPRES]
rate_NN
bearing_GER
Weighted_NN
Total_NN
financial_JJ
financial_JJ
for_PIN
which_WDT [PIRE]
rate_NN
financial_JJ
financial_JJ
average_JJ
time_NN
financial_JJ
liabilities_NOMZ
liabilities_NOMZ
is_VPRT [PASS]
fixed_VBN
liabilities_NOMZ
liabilities_NOMZ
to_PIN
maturity_NOMZ
liabilities_NOMZ
Currency_NN
000_CD
%_NN
months_NN
000_CD
000_CD
months_NN
000_CD
Sterling_GER
29,400_CD
6.00_CD
29.5_CD
30,000_CD
11,310_CD
40.0_CD
70,710_CD
Swiss_JJ
francs_NN
4,560_CD
3.64_CD
13.5_CD
4,897_CD
9,457_CD
Euro_NN
863_CD
6.25_CD
11.0_CD
201_CD
417.0_CD
1,064_CD
$_$
US_FPP1
25_CD
5.25_CD
40.0_CD
621_CD
3,269_CD
144.0_CD
3,915_CD
Swedish_NN
Krona_NN
319_CD
7.25_CD
27.8_CD
319_CD
35,167_CD
5.71_CD
27.0_CD
35,518_CD
14,780_CD
68.1_CD
85,465_CD
Financial_NN
liabilities_NOMZ
comprise_VPRT
total_JJ
borrowings_GER
of_PIN
10.0_CD
million_CD
2001_CD
:_:
14.4_CD
million_CD
,_,
convertible_JJ
bonds_NN
of_PIN
59.4_CD
million_CD
2001_CD
:_:
59.4_CD
million_CD
,_,
non-equity_JJ
Deferred_NN
A_NN
and_PHC
B_NN
Shares_NN
of_PIN
11.3_CD
million_CD
2001_CD
:_:
22.6_CD
million_CD
,_,
other_JJ
creditors_NN
of_PIN
4.6_CD
million_CD
2001_CD
:_:
5.1_CD
million_CD
and_CC
provisions_NN
of_PIN
0.2_CD
million_CD
2001_CD
:_:
0.1_CD
million_CD
._.
Total_JJ
financial_JJ
liabilities_NOMZ
does_VPRT
not_XX0
agree_VB [SUAV] [PUBV]
to_PIN
the_DT
total_NN
of_PIN
the_DT
balance_NN
sheet_NN
captions_NOMZ
due_JJ
to_PIN
the_DT
presence_NN
of_PIN
1,023,000_CD
2001_CD
:_:
1,438,000_CD
of_PIN
unamortised_JJ
issue_NN
costs_NN
within_PIN
the_DT
value_NN
shown_VBN [PRIV] [WZPAST]
on_PIN
the_DT
balance_NN
sheet_NN
for_PIN
convertible_JJ
bonds_NN
._.
All_QUAN
floating_VBG
rate_NN
financial_JJ
liabilities_NOMZ
,_,
in_PIN
both_DT
2002_CD
and_CC
2001_CD
,_,
are_VPRT
interest_NN
bearing_GER
financial_JJ
liabilities_NOMZ
that_TSUB
bear_VPRT
interest_NN
at_PIN
interest_NN
rates_NN
based_VBN [WZPAST]
on_PIN
LIBOR_NN
,_,
prime_JJ
and_PHC
other_JJ
bank_NN
based_VBN
lending_GER
rates_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
liability_NOMZ
arises_VPRT
,_,
which_WDT [SERE]
are_VPRT [PASS]
fixed_VBN
for_PIN
periods_NN
of_PIN
up_RB
to_PIN
12_CD
months_NN
._.
31_CD
December_NN
2001_CD
Weighted_JJ
average_JJ
interest_NN
rate_NN
Weighted_JJ
Non-interest_JJ
Fixed_JJ
rate_NN
on_PIN
fixed_VBN
average_JJ
time_NN
Floating_VBG [WZPRES]
rate_NN
bearing_GER
Weighted_NN
Total_NN
financial_JJ
financial_JJ
for_PIN
which_WDT [PIRE]
rate_NN
financial_JJ
financial_JJ
average_JJ
time_NN
financial_JJ
liabilities_NOMZ
liabilities_NOMZ
is_VPRT [PASS]
fixed_VBN
liabilities_NOMZ
liabilities_NOMZ
to_PIN
maturity_NOMZ
liabilities_NOMZ
Currency_NN
000_CD
%_NN
months_NN
000_CD
000_CD
months_NN
000_CD
Sterling_GER
59,400_CD
6.00_CD
41.5_CD
22,623_CD
52.0_CD
82,023_CD
Swiss_JJ
francs_NN
4,302_CD
3.63_CD
23.6_CD
5,548_CD
9,850_CD
French_JJ
Francs_NN
1,599_CD
6.25_CD
23.0_CD
745_CD
65_CD
419.0_CD
2,409_CD
$_$
US_FPP1
3,898_CD
3,385_CD
156.0_CD
7,283_CD
65,301_CD
5.85_CD
39.9_CD
10,191_CD
26,073_CD
66.4_CD
101,565_CD
75_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
c_NN
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Within_PIN
one_CD
year_NN
2,927_CD
7,257_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
5,256_CD
24,513_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
71,587_CD
64,009_CD
Beyond_NN
five_CD
years_NN
5,695_CD
5,786_CD
85,465_CD
101,565_CD
d_SYM
Borrowing_VBG
facilities_NOMZ
As_IN
at_PIN
31_CD
December_NN
2002_CD
the_DT
Group_NN
had_VBD
the_DT
following_VBG
undrawn_JJ
committed_JJ
borrowing_GER
facilities_NOMZ
available_JJ
._.
31_CD
December_NN
2002_CD
31_CD
December_NN
2001 000 000_CD
Expiring_VBG
within_PIN
one_CD
year_NN
1,646_CD
369_CD
e_SYM
Fair_NN
values_VPRT
The_DT
comparison_NN
of_PIN
fair_JJ
and_CC
book_NN
values_NN
of_PIN
all_QUAN
the_DT
Groups_NN
financial_JJ
instruments_NOMZ
as_IN
at_PIN
31_CD
December_NN
2002_CD
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Market_NN
value_NN
or_CC
Directors_NN
valuation_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
fixed_VBN
and_CC
current_JJ
asset_NN
investments_NOMZ
._.
Market_NN
values_NN
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
values_NN
of_PIN
all_QUAN
swaps_NN
and_CC
foreign_JJ
currency_NN
contracts_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
non-equity_JJ
Deferred_NN
B_NN
Shares_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
Ordinary_NN
Share_NN
price_NN
at_PIN
31_CD
December_NN
2002_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
Directors_NN
opinion_NN
that_TOBJ
12_CD
million_CD
Ordinary_NN
Shares_NN
will_PRMD
be_VB [PASS]
issued_VBN
in_PIN
settlement_NOMZ
of_PIN
the_DT
deferred_JJ
consideration_NOMZ
payable_JJ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
._.
See_VB [PRIV]
note_NN
22_CD
:_:
Share_NN
capital_NN
,_,
for_PIN
details_NN
of_PIN
the_DT
contingencies_NN
that_TSUB
shall_PRMD
determine_VB [SUAV] [PRIV]
the_DT
issuance_NN
of_PIN
the_DT
Ordinary_NN
Shares_NN
._.
The_DT
fair_JJ
values_NN
of_PIN
all_QUAN
other_JJ
items_NN
have_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
discounting_VBG
future_JJ
cash_NN
flows_VPRT
at_PIN
interest_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
31_CD
December_NN
2002_CD
._.
31_CD
December_NN
2002_CD
Book_NN
values_NN
Fair_NN
values_VPRT
Financial_NN
instruments_NOMZ
held_VBD [PRIV]
or_CC
issued_VBD
to_TO
finance_VB
the_DT
Groups_NN
operations_NOMZ
000_CD
000_CD
Fixed_VBN
asset_NN
investments_NOMZ
18,874_CD
17,287_CD
Current_JJ
asset_NN
investments_NOMZ
1,961_CD
1,961_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
7,394_CD
7,394_CD
Short-term_JJ
bank_NN
deposits_NN
20,667_CD
20,667_CD
Short-term_JJ
borrowings_GER
and_CC
current_JJ
portion_NOMZ
of_PIN
long-term_JJ
borrowings_GER
2,927_CD
2,927_CD
Long-term_JJ
convertible_JJ
debt_NN
59,400_CD
53,863_CD
Other_JJ
long-term_JJ
debt_NN
11,828_CD
11,707_CD
Non-equity_NOMZ
Deferred_VBN
B_NN
Shares_NN
11,310_CD
4,980_CD
36,569_CD
26,168_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
to_TO
manage_VB
the_DT
Groups_NN
currency_NN
profile_NN
Interest_NN
rate_NN
swaps_NN
452_CD
Euro_NN
currency_NN
options_NOMZ
85_CD
US$_$
currency_NN
options_NOMZ
13_CD
Forward_RB
currency_NN
contracts_NN
146_CD
500_CD
notes_NN
to_PIN
the_DT
financial_JJ
76_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
31_CD
December_NN
2001_CD
Book_NN
values_NN
Fair_NN
values_VPRT
Financial_NN
instruments_NOMZ
held_VBD [PRIV]
or_CC
issued_VBD
to_TO
finance_VB
the_DT
Groups_NN
operations_NOMZ
000_CD
000_CD
Fixed_VBN
asset_NN
investments_NOMZ
13,659_CD
13,903_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
4,534_CD
4,534_CD
Short-term_JJ
bank_NN
deposits_NN
22,358_CD
22,358_CD
Short-term_JJ
borrowings_GER
and_CC
current_JJ
portion_NOMZ
of_PIN
long_JJ
term_NN
borrowings_GER
7,257_CD
7,257_CD
Long-term_JJ
convertible_JJ
debt_NN
59,400_CD
50,194_CD
Other_JJ
long-term_JJ
debt_NN
12,288_CD
12,055_CD
Non-equity_JJ
Deferred_NN
A_NN
and_PHC
B_NN
Shares_NN
22,620_CD
14,700_CD
61,014_CD
43,411_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
to_TO
manage_VB
the_DT
Groups_NN
currency_NN
profile_NN
Euro_NN
currency_NN
options_NOMZ
38_CD
US$_$
currency_NN
options_NOMZ
20_CD
23_CD
Forward_RB
currency_NN
contracts_NN
46_CD
20_CD
31_CD
f_SYM
Currency_NN
exposures_NN
The_DT
following_JJ
analysis_NN
shows_VPRT [PRIV]
the_DT
net_JJ
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
group_NN
companies_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
their_TPP3
functional_JJ
currency_NN
and_ANDC
therefore_CONJ
give_VB
rise_VB
to_TO
exchange_VB
gains_NN
and_PHC
losses_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
both_DT
2002_CD
and_CC
2001_CD
._.
31_CD
December_NN
2002_CD
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
Swiss_JJ
$_$
Sterling_GER
$_$
US_FPP1
Euro_NN
francs_NN
Canadian_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Operating_VBG
Company_NN
000 000 000 000_CD
000_CD
000_CD
Sterling_GER
2,232_CD
617_CD
1_CD
2,850_CD
$_$
US_FPP1
15,956_CD
9_CD
34_CD
15,999_CD
Euro_NN
2,025_CD
96_CD
2,225_CD
296_CD
Swiss_JJ
francs_NN
928_CD
3,142_CD
528_CD
582_CD
1,104_CD
$_$
Canadian_JJ
1,904_CD
400 130 550_CD
2,724_CD
Swedish_NN
Krona_NN
1,343_CD
1,343_CD
18,348_CD
5,870_CD
50_CD
2,775_CD
615_CD
10,368_CD
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
31_CD
December_NN
2001_CD
French_JJ
Swiss_JJ
Sterling_GER
$_$
US_FPP1
francs_NN
francs_NN
Other_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Operating_VBG
Company_NN
000 000 000 000_CD
000_CD
000_CD
Sterling_GER
11,527_CD
49_CD
11,478_CD
$_$
US_FPP1
5,231_CD
5,231_CD
French_JJ
francs_NN
2,260_CD
102_CD
25_CD
2,133_CD
Swiss_JJ
francs_NN
3,568_CD
4,087_CD
406_CD
10_CD
8,071_CD
$_$
Canadian_JJ
477_CD
477_CD
3,923_CD
16,193_CD
406_CD
25_CD
39_CD
12,662_CD
77_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
g_JJ
Hedging_GER
As_IN
explained_VBN [PUBV]
above_PLACE
,_,
the_DT
Groups_NN
policy_NN
is_VPRT
to_TO
hedge_VB
interest_NN
rate_NN
exposures_NN
through_PIN
the_DT
use_NN
of_PIN
interest_NN
rate_NN
swaps_NN
and_PHC
currency_NN
exposures_NN
through_PIN
the_DT
use_NN
of_PIN
currency_NN
options_NOMZ
,_,
accrual_NN
forward_RB
options_NOMZ
and_CC
forward_JJ
currency_NN
contracts_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
off-balance_JJ
sheet_NN
unrecognised_JJ
and_PHC
on-balance_JJ
sheet_NN
deferred_VBN
gains_NN
and_PHC
losses_NN
in_PIN
respect_NN
of_PIN
hedges_NN
at_PIN
the_DT
beginning_GER
and_PHC
end_NN
of_PIN
the_DT
year_NN
:_:
31_CD
December_NN
2002_CD
Unrecognised_NN
Deferred_NN
Gains_NN
Losses_NN
Net_JJ
Total_JJ
Gains_NN
Losses_NN
Net_JJ
Total_JJ
000 000 000 000_CD
000_CD
000_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
1_CD
January_NN
2002_CD
31_CD
31_CD
20_CD
20_CD
Changes_NN
in_PIN
value_NN
from_PIN
1_CD
January_NN
2002_CD
to_PIN
settlement_NOMZ
262_CD
262_CD
Gains_NN
losses_NN
arising_VBG [WZPRES]
in_PIN
2001_CD
recognized_VBN [PRIV]
in_PIN
2002 231 231_CD
20_CD
20_CD
Gains_NN
losses_NN
not_XX0
recognized_VBN [PRIV]
in_PIN
2002_CD
arising_VBG
before_IN
1_CD
January_NN
2002_CD
Arising_VBG
in_PIN
2002_CD
598_CD
98_CD
500_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
31_CD
December_NN
2002_CD
598_CD
98_CD
500_CD
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
had_VBD
European_JJ
style_NN
accrual_NN
forward_RB
options_NOMZ
to_TO
purchase_VB
154,000_CD
of_PIN
Swiss_JJ
francs_NN
each_QUAN
week_NN
for_PIN
the_DT
26_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
July_NN
2002_CD
and_CC
71,000_CD
of_PIN
Euro_NN
each_QUAN
week_NN
for_PIN
the_DT
14_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
April_NN
2002_CD
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
had_VBD
agreements_NOMZ
in_PIN
place_NN
for_PIN
American_JJ
style_NN
accrual_NN
forward_RB
options_NOMZ
,_,
commencing_VBG [PRESP]
in_PIN
January_NN
2003_CD
,_,
to_TO
purchase_VB
113,000_CD
of_PIN
US_FPP1
dollars_NN
for_PIN
the_DT
44_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
November_NN
2003_CD
and_CC
44,000_CD
of_PIN
Swedish_JJ
Krona_NN
each_QUAN
week_NN
for_PIN
the_DT
45_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
November_NN
2003_CD
._.
Both_DT
of_PIN
these_DEMO
structures_NN
lapsed_VBD
in_PIN
January_NN
and_PHC
February_NN
2003_CD
respectively_RB
._.
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
Company_NN
had_VBD
forward_JJ
currency_NN
contracts_NN
to_TO
purchase_VB
4.5_CD
million_CD
of_PIN
Swiss_JJ
francs_NN
,_,
1.1_CD
million_CD
of_PIN
Euro_NN
and_CC
0.5_CD
million_CD
of_PIN
Swedish_NN
Krona_NN
._.
The_DT
excess_NN
of_PIN
fair_JJ
values_NN
over_IN
book_NN
values_NN
for_PIN
currency_NN
options_NOMZ
shown_VBN [PRIV] [WZPAST]
in_PIN
note_NN
25_CD
e_SYM
represents_VPRT
the_DT
unrecognised_JJ
hedging_GER
gain_NN
on_PIN
these_DEMO
instruments_NOMZ
as_IN
at_PIN
31_CD
December_NN
2002_CD
._.
The_DT
actual_JJ
gains_NN
or_CC
losses_NN
arising_VBG [WZPRES]
on_PIN
these_DEMO
currency_NN
options_NOMZ
will_PRMD
be_VB [BEMA]
dependent_PRED
on_PIN
future_JJ
exchange_NN
rates_NN
and_CC
will_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
in_PIN
2003_CD
,_,
as_IN
the_DT
operational_JJ
transactions_NOMZ
to_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
linked_VBN
occur_VPRT
._.
Unrecognised_JJ
gains_NN
at_PIN
31_CD
December_NN
2002_CD
include_VPRT
0.5_CD
million_CD
in_PIN
relation_NOMZ
to_PIN
the_DT
cancellable_JJ
swap_NN
agreement_NOMZ
._.
This_DEMP
is_VPRT [PASS]
based_VBN
upon_PIN
the_DT
swap_NN
agreement_NOMZ
continuing_VBG [WZPRES]
for_PIN
the_DT
life_NN
of_PIN
the_DT
convertible_JJ
bond_NN
and_CC
as_IN
such_JJ
the_DT
gain_NN
would_PRMD
be_VB [PASS]
spread_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
until_IN
2005_CD
._.
The_DT
Royal_NN
Bank_NN
of_PIN
Scotland_NN
exercised_VBD
its_PIT
right_NN
to_TO
cancel_VB
the_DT
swap_NN
on_PIN
19_CD
December_NN
2001_CD
and_CC
was_VBD [PASS]
replaced_VBN
with_PIN
a_DT
comparable_JJ
swap_NN
on_PIN
27_CD
February_NN
2002_CD
._.
Similarly_CONJ
,_,
it_PIT
was_VBD [SPAU] [PASS]
again_TIME
canceled_VBN
and_PHC
replaced_VBN
on_PIN
15_CD
December_NN
2002_CD
._.
31_CD
December_NN
2001_CD
Unrecognised_NN
Deferred_NN
Gains_NN
Losses_NN
Net_JJ
Total_JJ
Gains_NN
Losses_NN
Net_JJ
Total_JJ
000 000 000 000_CD
000_CD
000_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
1_CD
January_NN
2001_CD
1,043_CD
104_CD
939_CD
Changes_NN
in_PIN
value_NN
from_PIN
1_CD
January_NN
2001_CD
to_PIN
settlement_NOMZ
923 104 819_CD
Gains_NN
losses_NN
arising_VBG [WZPRES]
in_PIN
2000_CD
recognized_VBN [PRIV]
in_PIN
2001 120 120_CD
Gains_NN
losses_NN
not_XX0
recognized_VBN [PRIV]
in_PIN
2001_CD
arising_VBG
before_IN
1_CD
January_NN
2001_CD
Arising_VBG
in_PIN
2001_CD
31_CD
31_CD
20_CD
20_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
31_CD
December_NN
2001_CD
31_CD
31_CD
20_CD
20_CD
notes_NN
to_PIN
the_DT
financial_JJ
78_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
26_CD
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
operates_VPRT
various_JJ
defined_VBN
contribution_NOMZ
plans_NN
for_PIN
its_PIT
employees_NN
in_PIN
the_DT
UK_NN
,_,
Switzerland_NN
,_,
US_FPP1
,_,
Sweden_NN
and_PHC
Canada_NN
._.
The_DT
Groups_NN
contributions_NOMZ
to_PIN
these_DEMO
plans_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
period_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
,_,
and_ANDC
the_DT
assets_NN
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
separate_JJ
trustee_NN
administered_VBN
funds_NN
._.
The_DT
Group_NN
operates_VPRT
an_DT
unfunded_JJ
defined_VBN
benefit_NN
scheme_NN
in_PIN
respect_NN
of_PIN
its_PIT
employees_NN
in_PIN
France_NN
based_VBN [WZPAST]
on_PIN
the_DT
national_JJ
collective_JJ
agreement_NOMZ
of_PIN
the_DT
pharmaceutical_JJ
industry_NN
,_,
and_ANDC
a_DT
provision_NN
of_PIN
201,000_CD
is_VPRT [PASS]
included_VBN
in_PIN
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
note_VPRT [PRIV]
18_CD
._.
The_DT
charge_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
128,000_CD
._.
Under_IN
the_DT
transitional_JJ
provisions_NN
of_PIN
FRS17_NN
:_:
Retirement_NOMZ
Benefits_NN
certain_JJ
disclosures_NN
for_PIN
the_DT
defined_VBN
benefit_NN
scheme_NN
in_PIN
France_NN
are_VPRT [PASS]
required_VBN [SUAV]
as_IN
follows_VPRT
:_:
As_IN
at_PIN
December_NN
2002_CD
a_DT
valuation_NOMZ
was_VBD [BYPA]
performed_VBN
by_PIN
professionally_RB
qualified_VBN
actuaries_NN
on_PIN
the_DT
present_JJ
value_NN
of_PIN
the_DT
accrued_VBN
liabilities_NOMZ
calculated_VBN [PRIV]
under_IN
the_DT
projected_VBN
unit_NN
method_NN
._.
The_DT
principal_JJ
assumptions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
actuaries_NN
were_VBD
:_:
2002_CD
2001_CD
%_NN
per_PIN
annum_NN
%_NN
per_PIN
annum_NN
Inflation_NOMZ
rate_NN
1.75_CD
2.0_CD
Rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
2.75_CD
3.0_CD
Discount_NN
rate_NN
5.25_CD
5.5_CD
Analysis_NN
of_PIN
amounts_NN
charged_VBN [WZPAST]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
respect_NN
of_PIN
the_DT
defined_VBN
benefit_NN
scheme_NN
2002_CD
000_CD
Current_JJ
service_NN
cost_NN
24_CD
Past_NN
service_NN
cost_NN
Interest_NN
on_PIN
pension_NN
scheme_NN
liabilities_NOMZ
21_CD
Total_JJ
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
45_CD
Movement_NOMZ
in_PIN
deficit_NN
during_PIN
the_DT
year_NN
2002_CD
000_CD
At_PIN
1_CD
January_NN
2002_CD
382_CD
Exchange_NN
adjustment_NOMZ
25_CD
Total_JJ
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
45_CD
Benefit_NN
payments_NOMZ
made_VBD
9_CD
Actuarial_NN
gain_NN
recognized_VBD [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
61_CD
At_PIN
31_CD
December_NN
2002_CD
382_CD
79_CD
26_CD
Pension_NN
arrangements_NOMZ
continued_VBD
Amounts_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
under_IN
FRS17_NN
Experience_NN
gains_NN
arising_VBG [WZPRES]
on_PIN
scheme_NN
liabilities_NOMZ
000_CD
17_CD
Percentage_NN
of_PIN
scheme_NN
liabilities_NOMZ
%_NN
4_CD
Changes_NN
in_PIN
assumption_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
000_CD
44_CD
Percentage_NN
of_PIN
scheme_NN
liabilities_NOMZ
%_NN
12_CD
Total_JJ
actuarial_JJ
gain_NN
000_CD
61_CD
Percentage_NN
of_PIN
scheme_NN
liabilities_NOMZ
%_NN
16_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
under_IN
FRS17_NN
000_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
per_PIN
balance_NN
sheet_NN
264,006_CD
Pension_NN
liability_NOMZ
under_IN
FRS17_NN
382_CD
Pension_NN
liability_NOMZ
under_IN
SSAP24_CD
201_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
under_IN
FRS17_NN
264,187_CD
Net_JJ
assets_NN
under_IN
FRS17_NN
000_CD
Net_JJ
assets_NN
per_PIN
balance_NN
sheet_NN
124,270_CD
Pension_NN
liability_NOMZ
under_IN
FRS17_NN
382_CD
Pension_NN
liability_NOMZ
under_IN
SSAP24_NN
201_CD
Net_JJ
assets_NN
under_IN
FRS17_NN
124,089_CD
27_CD
Acquisitions_NOMZ
a_DT
Drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
On_PIN
13_CD
May_POMD
2002_CD
SkyePharma_NN
acquired_VBD
the_DT
entire_JJ
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
,_,
of_PIN
Sweden_NN
,_,
for_PIN
3.6_CD
million_CD
in_PIN
cash_NN
including_VBG [WZPRES]
acquisition_NOMZ
costs_NN
and_CC
the_DT
assumption_NOMZ
of_PIN
0.4_CD
million_CD
of_PIN
net_JJ
liabilities_NOMZ
._.
The_DT
acquired_VBN
rights_NN
include_VPRT
Bioglans_NN
Biosphere_NN
injectable_JJ
technology_NN
and_CC
those_DEMO
rights_NN
to_PIN
DermaStick_NN
,_,
Crystalip_NN
and_PHC
ES-Gel_NN
topical_JJ
drug_NN
delivery_NN
technologies_NN
that_TSUB
remained_VBD
with_PIN
Bioglan_NN
after_IN
the_DT
January_NN
2001_CD
development_NOMZ
and_PHC
commercialisation_NOMZ
licensing_GER
agreement_NOMZ
._.
The_DT
acquisition_NOMZ
method_NN
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
and_CC
goodwill_NN
of_PIN
4.0_CD
million_CD
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
._.
By_PIN
consideration_NOMZ
of_PIN
the_DT
likely_JJ
commercial_JJ
life_NN
of_PIN
the_DT
technology_NN
acquired_VBN
,_,
the_DT
Directors_NN
have_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
a_DT
suitable_JJ
period_NN
over_IN
which_WDT
to_TO
amortise_VB
the_DT
goodwill_NN
is_VPRT [BEMA]
20_CD
years_NN
._.
Book_NN
values_NN
and_CC
fair_JJ
values_NN
000_CD
Fixed_JJ
assets_NN
Tangible_JJ
assets_NN
676_CD
Current_JJ
assets_NN
Debtors_NN
44_CD
Creditors_NN
amounts_VPRT
falling_VBG
due_JJ
within_PIN
one_CD
year_NN
1,095_CD
Net_JJ
current_JJ
liabilities_NOMZ
1,051_CD
Net_JJ
liabilities_NOMZ
375_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
3,500_CD
Expenses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
transaction_NOMZ
95_CD
Consideration_NOMZ
3,595_CD
Goodwill_NN
3,970_CD
notes_NN
to_PIN
the_DT
financial_JJ
80_CD
statements_NOMZ
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
27_CD
Acquisitions_NOMZ
continued_VBD
Results_NN
of_PIN
the_DT
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
The_NN
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
prior_RB
to_PIN
the_DT
acquisition_NOMZ
formed_VBD
part_NN
of_PIN
Bioglan_NN
AB_NN
and_CC
did_VBD
not_XX0
report_VB [PUBV]
as_IN
a_DT
separate_JJ
unit_NN
._.
During_PIN
the_DT
period_NN
13_CD
May_POMD
2002_CD
to_PIN
31_CD
December_NN
2002_CD
the_DT
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
contributed_VBD
0.5_CD
million_CD
to_PIN
turnover_NN
,_,
a_DT
loss_NN
of_PIN
1.5_CD
million_CD
to_TO
operating_VBG
profit_NN
and_CC
a_DT
cash_NN
outflow_NN
of_PIN
1.3_CD
million_CD
to_PIN
net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
._.
b_NN
RTP_NN
Pharma_NN
Inc._NN
._.
SkyePharma_NN
achieved_VBD
control_NN
of_PIN
RTP_NN
Pharma_NN
Inc._NN
in_PIN
December_NN
2001_CD
when_RB
agreement_NOMZ
was_VBD [PASS]
reached_VBN
to_TO
acquire_VB
the_DT
majority_NOMZ
of_PIN
the_DT
outstanding_JJ
voting_NN
shares_NN
in_PIN
RTP_NN
._.
As_IN
part_NN
of_PIN
the_DT
RTP_NN
acquisition_NOMZ
deferred_VBD
consideration_NOMZ
may_POMD
be_VB [BEMA]
due_PRED
to_TO
be_VB [BEMA]
the_DT
former_JJ
RTP_NN
shareholders_NN
._.
See_VB [PRIV]
note_NN
23_CD
b_NN
:_:
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
._.
No_SYNE
material_NN
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
the_DT
provisional_JJ
fair_JJ
values_NN
._.
28_CD
Related_VBN
party_NN
transactions_NOMZ
At_PIN
the_DT
end_NN
of_PIN
December_NN
1998_CD
,_,
Ian_NN
Gowrie-Smith_NN
through_PIN
a_DT
family-owned_JJ
trust_NN
acquired_VBD
a_DT
50_CD
%_NN
interest_NN
in_PIN
10_CD
East_NN
63rd_NN
Street_NN
Inc._NN
the_DT
company_NN
which_WDT [WHSUB]
owns_VPRT
10_CD
East_NN
63rd_NN
Street_NN
,_,
a_DT
property_NN
in_PIN
New_NN
York_NN
._.
In_PIN
December_NN
2002_CD
Mr_NN
Gowrie-Smith_NN
acquired_VBD
the_DT
remaining_VBG
50_CD
%_NN
interest_NN
._.
SkyePharma_NN
PLC_NN
has_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
occupation_NOMZ
of_PIN
that_DEMO
property_NN
since_OSUB
January_NN
1997_CD
,_,
subject_JJ
to_PIN
a_DT
tenancy_NN
agreement_NOMZ
renewed_VBN [WZPAST]
in_PIN
February_NN
2001_CD
at_PIN
which_WDT [PIRE]
time_NN
the_DT
annual_JJ
rent_NN
was_VBD [PASS]
increased_VBN
to_TO
$_$
360,000_CD
per_PIN
annum_NN
based_VBN [WZPAST]
upon_PIN
an_DT
independent_JJ
valuation_NOMZ
._.
On_PIN
1_CD
April_NN
2002_CD
the_DT
company_NN
took_VBD
additional_JJ
space_NN
within_PIN
the_DT
property_NN
at_PIN
which_WDT [PIRE]
time_NN
the_DT
annual_JJ
rent_NN
was_VBD [PASS]
increased_VBN
to_TO
$_$
420,000_CD
per_PIN
annum_NN
._.
Until_IN
1_CD
April_NN
2002_CD
approximately_RB
one-third_NN
of_PIN
the_DT
premises_NN
was_VBD [PASS]
subleased_VBN
to_PIN
Fifth_NN
Avenue_NN
Capital_NN
Inc._NN
an_DT
unrelated_JJ
company_NN
._.
29_CD
Principal_NN
subsidiary_NN
undertakings_GER
Company_NN
Country_NN
of_PIN
incorporation_JJ
%_NN
Held_NN
Principal_NN
activities_NOMZ
1_CD
and_CC
2_CD
SkyePharma_NN
Canada_NN
Holdings_GER
Inc._NN
._.
Canada_NN
100_CD
Holding_GER
company_NN
2_CD
SkyePharma_NN
Canada_NN
Inc._NN
._.
Canada_NN
100_CD
Research_NN
and_PHC
development_NOMZ
1_CD
SkyePharma_NN
Production_NOMZ
SAS_NN
France_NN
100_CD
Manufacturing_GER
of_PIN
pharmaceuticals_NN
Krypton_NN
Limited_NN
Gibraltar_NN
100_CD
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
1_CD
SkyePharma_NN
AB_NN
Sweden_NN
100_CD
Research_NN
and_PHC
development_NOMZ
Jago_NN
Holding_GER
AG_NN
Switzerland_NN
100_CD
Holding_GER
company_NN
Jago_NN
Research_NN
AG_NN
Switzerland_NN
100_CD
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
Jagotec_NN
AG_NN
Switzerland_NN
100_CD
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
SkyePharma_NN
AG_NN
Switzerland_NN
100_CD
Research_NN
and_PHC
development_NOMZ
1_CD
SkyePharma_NN
Holding_GER
AG_NN
Switzerland_NN
100_CD
Holding_GER
company_NN
1_CD
SkyePharma_NN
Holding_GER
Inc._NN
._.
US_FPP1
100_CD
Holding_GER
company_NN
SkyePharma_NN
Inc._NN
._.
US_FPP1
100_CD
Development_NOMZ
of_PIN
pharmaceuticals_NN
SkyePharma_NN
US_FPP1
Inc._NN
._.
US_FPP1
100_CD
Development_NOMZ
of_PIN
pharmaceuticals_NN
and_PHC
licensing_GER
1_CD
Denotes_NN
investment_NOMZ
directly_RB
held_VBN [PRIV]
by_PIN
the_DT
Company_NN
._.
2_CD
On_PIN
1_CD
January_NN
2003_CD
SkyePharma_NN
Canada_NN
Holdings_GER
Inc._NN
and_PHC
SkyePharma_NN
Canada_NN
Inc._NN
were_VBD [PASS]
amalgamated_VBN
under_IN
Canadian_JJ
Law_NN
._.
The_DT
name_NN
of_PIN
the_DT
amalgamated_JJ
corporation_NOMZ
is_VPRT
SkyePharma_NN
Canada_NN
Inc._NN
._.
Full_JJ
details_NN
of_PIN
all_QUAN
subsidiary_NN
undertakings_GER
will_PRMD
be_VB [PASS]
attached_VBN
to_PIN
the_DT
Companys_NN
Annual_JJ
Return_NN
to_TO
be_VB [PASS]
filed_VBN
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
